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 Introduction 
 Mast cells 
Mast cells (MCs) are potent immunomodulatory cells that were first discovered in the late 
nineteenth century by Paul Ehrlich. These cells are enriched with cytoplasmic granules that 
exhibit metachromatic staining with blue aniline dyes (Crivellato et al., 2003). MCs are 
predominantly present in the dermal and subcutaneous layers of the skin, in close proximity 
to blood vessels, and are also found within the airways, the gastrointestinal tract, and in hair 
follicles, often in close contact with neurons and smooth muscle cells (Abraham and St John, 
2010; Yong, 1997). Due to their preferred location, namely in tissues exposed to the external 
environment, they are one of the first immune cells to interact with invading pathogens or 
antigens. MCs are best known for their pro-inflammatory response in allergic disorders and 
their protective role in parasite infections. Furthermore, several studies have described the 
possible role of MCs in wound healing, tissue remodelling and transplant tolerance (Lu et al., 
2006; Trautmann et al., 2000). Conversely, MCs have also been reported to exacerbate 
rheumatoid arthritis, multiple sclerosis, atherosclerosis and cancerogenesis (Coussens et al., 
1999; Secor et al., 2000; Sun et al., 2007). Thus, MCs are regarded as a critical regulatory 
cell of the immune system. 
 Mast cell development 
Mast cells were originally considered to be derived from T lymphocytes, macrophages or 
fibroblasts; however, Kitamura et al. demonstrated with an in vivo murine experiment that 
MCs originate from haematopoietic cells in the bone marrow (Kitamura et al., 1978; Kitamura 
et al., 1981). Haematopoietic stem cells (HSCs) give rise to immature mast cell progenitors 
(MCP) that circulate in blood. These progenitor cells migrate to peripheral tissues (skin or 
mucosa), where they differentiate into mature MCs under the influence of tissue-specific 
growth factors (Figure 1.1). In mice, MC precursors appear in the yolk sac as early as day 
9.5 of gestation, peak at day 11 and decline after day 13 (Sonoda et al., 1983). Numbers of 
MC precursors increase at day 15 in the fetal liver and in the blood at day 15.5 of gestation 
(Rodewald et al., 1996). In the C57BL/6 mouse line, mature MCs were found in embryonic 
skin at day 17 (Gurish and Austen, 2012). The development of MCPs to mature MCs is strictly 
dependent on the tissue microenvironment and on growth factors.  
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The Kit gene is a proto-oncogene originally discovered as the cellular homolog (c-Kit) of the 
feline sarcoma virus oncogene C-KIT (Besmer et al., 1986). C-kit, a receptor tyrosine kinase, 
binds the cytokine, stem cell factor (SCF), which exists both as a transmembrane and as a 
soluble protein. C-Kit/SCF binding results in receptor homo-dimerization and the auto-
phosphorylation of tyrosine residues. C-Kit activates multiple signalling cascades (RAS/ERK, 
PI3/Kinase, Src kinase and JAK/STAT pathways). Signalling through Kit and its resultant 
downstream signalling is essential for MC survival, differentiation and proliferation. The c-kit 
receptor is expressed on all haematopoietic progenitors (Rodewald et al., 1996). During 
differentiation, all lineages downregulate the c-kit receptor. The only exception to this is the 
MC lineage, as MCPs and MCs retain c-kit expression that allows SCF signalling through all 
stages of the MC development (Arinobu et al., 2005; Metcalfe et al., 1997). Mouse studies 
using mutations in the KIT or SL locus have demonstrated the critical role of the c-KIT and 
SCF interaction in MC development and survival. Deficiency of the Kit or Sl genes results in 
profound MC deficiency. In addition, interleukins (ILs) such as IL-4, IL-9, IL-10 and IL-33, and 
 
Figure 1.1: Development of mast cells. Haematopoietic stem cells (HSC) give rise to immature mast cell 
progenitors (MCPs) that circulate in blood and enter peripheral tissues to differentiate locally into 
cutaneous connective tissue mast cells and mucosal mast cells in the skin and gut respectively. Figure 
modified from (Galli et al., 2008a). 
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nerve growth factor (NGF), further support the maturation and enhance the survival of MCs 
in peripheral tissues (Gurish and Austen, 2012; Kashiwakura et al., 2011; Okayama and 
Kawakami, 2006). 
 Heterogeneity of mast cells 
MCs are classified into two types, namely connective tissue mast cells (CTMCs) and mucosal 
mast cells (MMCs) based on their staining characteristics and differences in development, 
localisation, morphology and granular content. More than 50% of the MC cytoplasm is filled 
with granules (Thakurdas et al., 2007) that are rich in histamine, heparin, proteases and lipid 
derivatives. Tissue fixation and histochemical staining conditions used to discriminate MMCs 
and CTMCs were first established by Enerback et al. (Kitamura, 1989). CTMCs stain blue 
with Alcian blue; MMC granules stain red with safranin. Morphologically, CTMCs are larger 
in size than MMCs, different in shape and contain more granules than MMCs. Mouse 
cutaneous MCs contain 10 pg of histamine per cell, whereas 0.1 pg of histamine is found in 
MMCs. The concentration of histamine is similar (3 – 8 pg/cell) in human MCs isolated from 
skin and lung tissue (Nakano et al., 1985). 
 
Heparin is the predominant type of proteoglycan found in CTMCs, whereas MMCs synthesize 
chondroitin sulfate proteoglycans. In rodent studies, it is evident that, upon helminth infection, 
rat MMCs isolated from small intestine tissue synthesise highly sulfated chondroitin 
proteoglycans. After proteoglycans, proteases are a quantitatively important fraction of the 
granular content of MCs. Three types of protease have been observed in MCs, namely the 
metalloproteinase carboxypeptidase A3 (CPA3) and the murine serine mast cell proteases 
(mMCP), which have chymotryptic (chymase) or tryptic (tryptase) activity (Gurish and Austen, 
2012). Cutaneous MCs found in mouse skin express CPA3, the chymases mMCP-4 and 
mMCP-5, and the tryptase mMCP-6 (Xing et al., 2011). In contrast, MMCs found in the 
intestine express only the chymases mMCP-1 and mMCP-2 upon helminth infection (Friend 
et al., 1996). As in rodents, human MC subpopulations are divided into two types, namely 
MCTC cells, designated by their tryptase and chymase content, and MCT cells, which contain 
tryptase alone. MCTCs predominantly appear in skin and in the submucosa of the small 
intestine, whereas MMCs appear in the mucosa of the small intestine. Therefore, in terms of 
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tissue localisation, human MCTs are similar to murine mucosal MMCs, whereas MCTCs are 
similar to the murine cutaneous CTMCs (Metcalfe et al., 1997). 
 Mast cell activation 
MCs are found particularly in locations that are in close contact with the external environment, 
such as the skin, airways, and intestine. MCs are armed with a multitude of receptors that 
belong to the large family of pattern recognition receptors (PRRs). Toll-like receptors (TLRs) 
are an important group of this family. These allow MCs to recognise microbial and 
endogenous tissue damage-associated structures (Supajatura et al., 2002, Matsushima et 
al., 2004). MCs also express FceR1-alpha receptors. This high-affinity IgE receptor, also 
known as FcεRI (Fc epsilon RI), is the high-affinity receptor for the Fc region of 
immunoglobulin E (IgE), an antibody involved in allergic disorders and anti-parasite immunity. 
MCs can be activated by multivalent allergens via specific IgE antibodies bound to the surface 
FcεRI. FcεRI is a tetrameric protein complex consisting of an IgE-binding α chain, a single β 
chain and two disulfide-linked γ chains. Activation can be achieved when approximately 100 
FcεRI receptors per MC aggregate with antigen (from a total of 3 x 105 FcεRI receptors per 
MC). Binding of IgE to FcεRI occurs at a 1:1 stoichiometry, and is highly specific and 
irreversible. Crosslinking of FcεRI-bound IgE molecules can induce receptor phosphorylation 
within seconds. The subsequent recruitment and activation of the kinase Syk induces various 
signal transduction pathways, resulting in three downstream effector responses in MCs: (1) 
granule exocytosis or degranulation, (2) synthesis and release of arachidonic acid from 
phospholipids, and (3) induction of pro-inflammatory gene expression. MC activation can be 
regulated by the inhibitory receptor FcγRIIB, which is expressed on the surface of each MC 
(Hitomi et al., 2010; Kraft and Kinet, 2007). The binding of FcgRIIB with FcεRI or FcgRIII by 
IgG immune complexes results in the downregulation of the secretory response (Ott and 
Cambier, 2000; Tkaczyk et al., 2004). In addition to IgE crosslink, MCs can also be activated 
by other stimuli, including neuropeptides, complement components, compound 48/80 and 
opiates (Metcalfe et al., 1997). 
 
Depending on the type and concentration of the activation signal (antigen), MCs can release 
either all classes of mediators at high levels via degranulation or more selectively only certain 
mediators by secretion. Mast cell mediators are classified into three main classes. The 
preformed granule associated mediators that include histamine, serotonin, TNF, MC 
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proteases and secreted growth factors such as VEGF and FGF, have functions which include 
the induction of inflammation, regulation of vascular permeability, angiogenesis and the 
recruitment of effector cells and tissue remodelling. The newly-generated lipid mediators such 
as leukotriene (LT) C4 and prostaglandins resulting in tissue oedema and 
bronchoconstriction. 
Various cytokines and chemokines produced by MCs can be grouped as pro-inflammatory, 
immunomodulatory or anti-inflammatory molecules that influence adaptive and innate 
immune responses. The large variety of MC mediators, as well as their reported functions, 
are listed in Table 1.1 (Marshall, 2004). 
 
  
Table 1.1: Mast cell mediators and their proposed effector functions. Adapted and modified from 
(Marshall, 2004). 
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 Mouse models of mast cell deficiency 
To investigate the biological relevance of MCs in vivo, MC-deficient mouse models have been 
developed over the past three decades. Kit mutant mice carrying a mutation at either the 
dominant white-spotting (W) locus on chromosome 5, or at the steel locus (SI) on 
chromosome 10 are MC deficient but also feature numerous other phenotypic abnormalities. 
Among the four rodent strains, WBB6F1-KitW/Wv (mouse), C57BL/6-KitWsh/Wsh (mouse), Kit-Sl/Sld 
(mouse) and KitWs/Ws (rat), the most extensively studied are the KitW/Wv and KitWsh/Wsh mice 
(Reber et al., 2012). In the WBB6F1-KitW/Wv strain, the Kit gene is truncated on the W allele 
with the deletion of 78 amino acids, resulting in loss of the transmembrane domain of the c-
kit protein. KitW/W homozygotes die perinatally and the rare survivors are sterile. The KitW-v 
allele has a single point mutation at position 2007 (C-T) resulting in impaired c-kit kinase 
activity (Nocka et al., 1990). Mice homozygous for the KitWv allele are born alive, but are 
sterile and have severe macrocytic anaemia. KitWv heterozygotes are fertile and have a mild 
anaemia, with a diluted hair coat colour as well as a ventral white spot. The breeding of KitW+ 
with KitWv results in the WBB6F1-KitW/W-v strain (a hybrid of KitW/+ and KitWv/+), which is viable 
and fertile but has reduced kit expression and signal transduction, resulting in a severe MC 
deficiency. The number of MCs in these mice is less than 1% of that in the controls (the skin 
of KitW/Wv mice) (Kitamura et al., 1978). Therefore, this strain can be used as a MC deficiency 
model for the investigation of MC functions in vivo. In addition to MCs, however, Kit is also 
expressed by other haematopoietic and non-haematopoietic cell subsets. KitW/Wv mice are 
therefore deficient in erythrocytes, neutrophils, germ cells, melanocytes, certain 
subpopulations of intraepithelial T cells and intestinal pacemaker cells.  
 
The next most widely used MC deficiency model is the KitWsh/Wsh “sash” mouse. The KitWsh 
allele is a large inversion of a segment of the Chromosome 5 that impairs KIT expression. 
The mutation spontaneously arose in a cross the C3H/HeH mouse strain with the 101/H strain 
results in litters with the heterozygous inheritance of a mutation at the W locus, i.e., an 
inversion of a segment of chromosome 5. This inversion impairs c-kit receptor expression, 
resulting in severe MC deficiency. KitWsh/Wsh homozygote embryos express c/kit from E10.5 – 
E11.5. By 10 weeks of age, the mice are virtually MC deficient (Yamazaki et al., 1994). 
KitWsh/Wsh mice are fertile and not anaemic. These mice do not suffer from spontaneous 
pathologies affecting the skin, stomach or duodenum. However, these mice feature 
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spontaneous splenomegaly and are thrombocythemic (Grimbaldeston et al., 2005b; Nigrovic 
et al., 2008b). In addition, they develop mild cardiomegaly due to a disruption of the corin 
gene (Nigrovic et al., 2008b). The multiple alterations of the immune and other systems that 
characterize Kit mutant mice that are not directly related to the lack of MCs complicate 
interpretation of results obtained in these models. 
 
Gene targeting approaches more recently allowed generation of novel mouse models of Cre-
LoxP technology (conditional, i.e., Cell type specific or inducible mutagenesis in vivo (Indra 
et al., 1999)) allowing for investigation of in vivo MCs functions. These were based on 
selective expression of Cre recombinase in MCs using either bacterial artificial chromosome 
(BAC) transgene or knock in technology. The Roers group generated a novel Cre line 
expressing Cre under the control of the mast cell protease 5 promoter (Mcpt5-Cre) (Scholten 
et al., 2008a). The BAC constructs were injected into C57BL/6 oocytes for random integration 
into the mouse genome. This allowed the inactivation of genes in connective tissue type MCs 
with a high efficiency and selectivity while mucosal MCs do not express Cre. Another model 
used the FcεRIβ chain promoter to drive Cre expression in MCs (FcϵRIβCre) (Furumoto et 
al., 2011).  
 
Kit independent MC deficiency mouse models (constitutive or inducible) were also made 
possible using Cre-LoxP technology. Inducible MC deficiency can be achieved by breeding 
the MC-specific transgenic line Mcpt5-Cre to a Cre-inducible diphtheria toxin receptor (iDTR) 
line, which is characterised by the expression of a simian diphtheria toxin receptor (DTR), in 
cells that deleted a loxP-flanked stop cassette, by Cre-mediated recombination. Mcpt5-Cre 
iDTR mice are injected with Diphtheria toxin (DT) that binds to the receptors on the surface 
of Mcpt5-Cre expressing CTMCs, which leads to apoptosis of these cells. Three 
intraperitoneal administration of diphtheria toxin (DT) allowed the efficient and specific 
depletion of CTMCs in vivo without affecting any other haematopoietic subsets (Katz and 
Austen). A mouse model of constitutive MC deficiency was obtained by crossing the Mcpt5-
Cre mice with the R-DTA mouse line. These mice express diphtheria toxin (DT) under the 
control of a ubiquitously active promoter provided a loxP-flanked stop element was removed 
by Cre. The stop cassette prevents DT expression in the absence of Cre activity. Upon 
Cre/mediated recombination, DT is constitutively expressed in connective tissue MCs only 
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and induces apoptosis-like cell death that results in efficient and selective MC depletion 
without any detectable abnormalities in blood parameters or in other haematopoietic cells.  
 
Another model of MC-deficiency was generated by Rodewald group, who expressed Cre 
under the control of carboxypeptidase A3 (CPA3) promoter. Unexpectedly, CPA3Cre knock 
in mice were completely devoid of CTMCs and MMCs resulted in constitute depletion of MCs. 
The targeted insertion of improved Cre-recombinase (iCre) into the MC carboxypeptidase A3 
locus resulted in a very strong Cre expression in MCs, causing Cre-mediated genotoxicity via 
the recombination of endogenous imperfect lox P-like sites in the mouse genome (Naiche 
and Papaioannou, 2007; Schmidt-Supprian and Rajewsky, 2007). This results in a gross 
chromosomal aberrations and a DNA damage response that kills the MCs. Except for a mild 
reduction of basophils numbers, these animals featured completely normal hematopoietic 
and immune systems. 
 
These novel Kit-independent MC-deficient mice allowed for a reassessment of in vivo MC 
functions and permitted the elucidation of the role of MCs and MC-specific genes in various 
disease settings. 
 Mast cells in health and disease 
As mentioned above, the strategic position of MCs at body surfaces including skin, and the 
respiratory tract and intestine suggests that they have role in pathogen defense. Experiments 
in kit mutant mice and MC protease-deficient mice suggested the important contribution of 
MCs to host defences against many different infections, including Trichinella spiralis (Knight 
et al., 2000) and Leishmania major (Maurer et al., 2006). In addition, in vitro studies have 
shown that MCs are capable of phagocytosing pathogens (Abraham and Malaviya, 1997; Di 
Nardo et al., 2003).  
MCs produce many different growth factors, including nerve growth factor (NGF), platelet-
derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth 
factor (2FGF2), histamine and tryptase, which are believed to be involved in wound healing 
and tissue remodelling (Table 1.1). Studies using kit mutants have suggested that wound 
closure is dependent on MCs (Weller et al., 2006).  
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MC activation in IgE-dependent allergic reactions are classified as type I or immediate 
hypersensitivity reactions. Crosslinking of FcεRI-bound IgE by multivalent antigens leads to 
degranulation and the release of various preformed mediators (Table 1.1), such as histamine, 
prostaglandins, leukotrienes and TNF, causing the immediate allergic response. This 
response can result in allergic asthma, rhinitis, conjunctivitis, atopic dermatitis or food 
allergies; in severe cases, exaggerated immediate allergic hypersensitivity reactions can 
cause life-threatening conditions, such as anaphylaxis (Rodewald and Feyerabend, 2012). 
Using Cre-loxp based MC deficient mouse models, the role of MCs in various diseases has 
been reinvestigated. The expression of Cre recombinase from the MC carboxypeptidase A 
(Cpa3) locus selectively depletes MCs in vivo (Katz and Austen). Unexpectedly, Cpa3Cre/+ 
(Cre master mice, Cre-mediated MC eradication) mice are fully susceptible to an autoimmune 
inflammatory arthritis that is induced by sera of KBxN mice, which provides glucose 6-
phosphate isomerase autoantibodies to form immune complexes (Feyerband et al; 2011). 
Similarly, experimental autoimmune encephalomyelitis, previously reported to be diminished 
in kit mutants, does not show MC dependency in Cpa3 mice. Therefore, Cpa3 mice are 
resistant to passive local and systemic IgE-mediated anaphylaxis (Katz and Austen). Our 
group has shown that MCs are necessary for the induction of contact allergy, and that in the 
absence of MCs, the T cell allergic response is diminished (Dudeck et al.) This finding is in 
conflict with an earlier report on the suppressive effects of MCs in contact hypersensitivity, 
which was based on experiments in kit mutant mice. Thus, reinvestigating the role of MCs 
using non-kit dependent MC deficient mouse models in various disease settings will allow the 
contributions of MCs to immune and inflammatory responses to be accurately defined. 
 Carcinogenesis 
Various mouse tumour models were key to delineate molecular mechanism the concept that 
of cancerogenesis. Cancer develops by a multistep process that requires at least six 
biological capabilities that distinguish a normal from a malignant cell (Hanahan and Weinberg, 
2000).These cancer hallmarks are (1) self-sufficiency in growth signals, (2) insensitivity to 
anti-growth signals, (3) tissue invasion and metastasis, (4) evasion from  apoptosis, (5) 
promotion of angiogenesis and (6) limitless replicative potential (Hanahan and Weinberg, 
2000); Figure 1.2). 
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 Mast cells in carcinogenesis 
Accumulation of MCs is an early and persistent event prominent in various human cancers. 
The presence of MCs at the tumour periphery was first reported in 1891 by Westphal. MC 
density has been correlated with poor prognosis in various solid tumours, including pancreatic 
cancer, intestinal polyps, squamous cell carcinoma (SCC) and melanoma (Coussens et al., 
1999; Gounaris et al., 2007; Ribatti et al., 2003; Soucek et al., 2007). The recruitment of MCs 
in stroma and along the invasion front of numerous tumours, suggested that MCs play an 
important role in tumour biology (Coussens et al., 1999; Gounaris et al., 2007; Soucek et al., 
2007). MCs secrete an array of mediators (Table 1.1) that could be either beneficial or 
detrimental to tumour growth. For instance, histamine, which is readily released upon 
degranulation, acts as an immune suppressor in the tumour microenvironment. Growth 
factors such as CSF, NGF, PDGF, and SCF could enhance tumour growth, and heparin and 
VEGF induce tumour neo-angiogenesis. However, MC derived cytokines such as TNF and 
IL-4, could also induce the apoptosis of tumour cells. Interleukins 1, 2, 3, 5, 6, 9, 10, 13 and 
16 promote inflammation and leucocyte migration that could be detrimental to tumorigenesis 
(Theoharides and Conti, 2004). 
 
Figure 1.2: Biological capabilities acquired during carcinogenesis. Adapted from (Hanahan et al. 2000) 
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 Mast cells in epithelial cancers 
Mastocytosis in tumour stroma has been correlated with poor prognosis, increased 
metastasis, reduced survival in various human cancers (Maciel et al., 2015).  Molin et al 
showed the clinical importance of mast cell infiltration in a study consist of 123 Hodgkin 
lymphoma cancer patients, correlated with poor prognosis with nodular sclerosis. Hodgkin 
lymphomas are distinct than other lymphomas with the presence of few tumour cells, the 
Hodgkin and Reed-Sternberg (HRS) cells that express CD30. Mast cells were revealed with 
tryptase staining and these cells were detected in virtually every case of the Hodgkin's 
lymphoma. In addition to that, more than 50% of infiltrating mast cells were found to positive 
for CD30 ligand. Blockade of CD30L in human mast cell line HMC-1 resulted in less thymidine 
uptake in HRS tumor cells, suggesting that the mast cells may stimulate DNA synthesis in 
HRS cells by CD30L–CD30 interactions (Molin et al., 2002). Likewise, MCs has been 
implicated for the promoting angiogenesis in cancerogenesis. Elpek et al, showed the 
prognostic values of Mean vascular density (MVD) and mast cell density (MCD) were 
significantly correlated in squamous cell carcinoma of the oesophagus in humans. These 
results suggests that mast cel mayl promote tumor neo angiogenesis in human SCC (Elpek 
et al., 2001). Furthermore, Ribatti et al evaluated the prognostic significance of tumour 
microvascular density (MVD) and MCD in melanoma patients. Immuno histological staining 
showed a higher number of micro vessels and mast cells in melanoma lesions of poor 
prognosis. These data suggest that a close relationship between MCD and reveals, a 
prognostic significance of MCD in human melanoma (Ribatti et al., 2003). 
Likewise, Strouch et al have shown that mast cell infiltration significantly increased in 
pancreatic cancer compared to normal pancreatic tissue. This increase in mast cell density 
correlated with higher grade tumors (p<0.0001) and worse survival with elevated serum 
tryptase activity. Thus, tumour infiltrating mast cells are associated with worse prognosis also 
in pancreatic cancer (Strouch et al., 2010) Recently, Rao et al shown that the infiltrated mast 
cells in the tumour microenvironment enhance BCa metastasis via stimulating 
ERβ/CCL2/CCR2 EMT/MMP9 signals (Rao et al., 2016). Thus, mast cell infiltration is 
inevitable in numerous human cancers. 
Numerous murine tumour models have been used to address the relevance of MCs infiltration 
in cancerogenesis. The association of MCs with invasive adenocarcinoma of the colon has 
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been evaluated using murine models of intestinal polyposis (Gounaris et al., 2007). First, 
APCΔ468 mice were used; this is a mouse model of intestinal polyps that harbours a targeted 
insertion of truncating mutations in the APC gene. Neoplastic lesions were detected as early 
as two months after birth; these occurred due to loss of the heterozygosis of the wild-type 
(wt) APC allele. As in human cancers, MCs (both cutaneous and mucosal) infiltrate polyp 
tissue in high numbers (Gounaris et al., 2007).  
 
Studies using a pancreatic beta islet mouse tumour model (pIns-mycERTAM;RIP7-bcl-xL) 
have also shown that MCs are actively recruited in pIns-mycERTAM;RIP7-bcl-xL mice, a 
switchable mouse model of Myc-carcinogenesis in pancreatic beta cells (Soucek et al., 2007). 
The cDNA-encoding human c-Myc fused with the C terminus of the hormone binding region 
of the mutant murine estrogen receptor (c-MycERTAM), which is expressed in pancreatic 
beta cells under the control of an insulin promoter (pIns). In contrast, the Bcl-2 homolog Bcl-
xL is expressed under the control of the rat insulin promoter (RIP7). Double transgenic mice 
(pIns-mycERTAM;RIP7-bcl-xL) display normal pancreatic islet morphology in the absence of 
4-OHT. Upon 4-OHT treatment, in less than one week, these mice developed pancreatic 
carcinoma. MCs rapidly migrated into the mesenchyme adjacent to the islets within 24 hours 
of Myc activation. 
 
Another murine intestinal model, APC+/Min mice is the result of a single germ line mutation in 
the tumor suppressor gene Adenomatous polyposis coli (APC). Mice heterozygous for the 
APC+/Min allele develop multiple adenomas throughout the small intestine and colon in 100% 
of mice carrying the Min allele. Tumorigenesis in APC+/Min mice was observed in mice that 
were constantly fed a high fat diet. Again, increased MC infiltration into intestinal adenomas 
was observed.  
 
To investigate the association of MCs in the above mentioned murine tumor models, Mice 
were either crossed with the conventional Kit-mutant mouse, a mouse model of mast cell 
deficiency or reconstituted with kit-mutant bone marrow or treated with phramocological  (MC-
degranulation) inhibitors. First, to detect a causative link between MCs and intestinal cancer, 
haematopoietic chimeras were generated to achieve MC deficiency. First, polyp-prone 
APC∆468 mice were lethally irradiated to achieve MC deficiency; the immune system of the 
irradiated APC∆468 mice was then reconstituted using the bone marrow from either of wt 
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(ctrls), KitWsh/Wsh or Cd34-/-Cd43-/- mice. These chimeras were analysed for the kinetics of 
intestinal polyp development. MC depletion in APC∆468 mice resulted in a marked reduction 
in the frequency of polyp formation. Reduction of polyp diameter and angiogenesis, and low 
levels of TNF in APC∆468 Kit Wsh/Wsh mice suggest that MCs are an essential component 
in polyp formation (Gounaris et al., 2007). Moreover, studies in APC-Min+/-RAG-/- mice have 
shown no alteration in mastocytosis in adenocarcinoma, suggesting that the infiltration of 
MCs is independent of lymphocytes. 
 
Next, to determine the causative effects of MCs in Myc-induced pancreatic islets, a 
pharmacological approach was adopted. Here, pIns-mycERTAM;RIP7-bcl-xL mice were 
systemically treated with cromolyn, an inhibitor of MC degranulation. Beta cell tumours were 
completely abolished in mice treated with cromolyn, suggesting that MCs have a tumour 
promoting role in Myc-induced islet tumorigenesis. Similar observations were recorded in MC-
deficient pancreatic islets (pIns-myc+ bcl-xL+ KitWsh/Wsh). In addition, angiogenesis completely 
regressed and beta cell tumour expansion was completely abolished, suggesting that MCs 
are required for the expansion of Myc-induced pancreatic tumours (Soucek et al., 2007). 
However, the kit mutant mouse models with multiple physiological defects (section 1.5) that 
are not directly related to the lack of MCs limit the interpretation of the experimental results 
derived from these different mouse models of epithelial cancer. 
 
Studies conducted by Sinnamon et al showed, MCs have a protective role in APC+/Min mice, 
a mouse model of intestinal neoplasia (Sinnamon et al., 2008). To achieve MC deficiency, 
Sash mice (c-kitW-sh/W-sh), was crossed with the Min mouse. Depletion of MCs in APC+/Min 
mice resulted in larger benign tumours than in MC-competent littermate controls. In addition, 
MC deficiency also impairs apoptosis in adenomas, and MC deficient tumours have a reduced 
eosinophil infiltration. This is in contrast to the findings of an earlier report regarding the 
tumour-promoting function of MCs in intestinal carcinogenesis, which was based on 
experiments in kit mutant mice. Therefore, re-investigating the relevance of mast cells using 
kit-independent mast cell deficiency mouse models will allow the contributions of MCs in 
carcinogenesis to be accurately defined. 
 
In a recent study, the functional significance of MCs in carcinogenesis were analyzed using 
CreMaster mice, a non-kit independent mouse model that are characterized by Cre 
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recombinase-mediated mast cell eradication. Activin transgenic mice, that overexpress 
activin-A in keratinocytes under control of the keratin 14 promoter (Act mice) are 
characterized by enhanced granulation tissue formation and accelerated re-epithelialization 
after wounding and skin carcinogenesis. As these mice are more susceptible to skin 
carcinogenesis, these mice are subjected to topical application of DMPA/TPA, to serve as a 
model of chemical-induced carcinogenesis. Loss of mast cells was achieved by crossing the 
activing mice with CreMaster mice, which are characterized by Cre recombinase-mediated 
mast cell eradication. However, loss of MCs did not affected the protumorigenic activity in a 
model of chemically induced skin carcinogenesis. Furthermore, mast cell deficiency did not 
alter chemically induced angiogenesis and tumorigenesis in mice with normal activin levels. 
These results suggest that mast cells do not promote skin cancerogenesis which that is 
contradictory to the findings with Kit mutant mice. 
 
Another study also revealed the same phenomena, the tumour promoting role of mast cells 
in pancreatic cancer was evaluated with kit-independent mouse model of MC deficiency. A 
spontaneous mouse model of Kras-driven pancreatic ductal adenocarcinoma (PDAC) was 
generated by combining flippase-FRT (Flp-FRT) and Cre-loxP recombination technology, 
which possesses all the major hallmarks of human PDAC. In Pdx1-Flp;FSF-KrasG12D/+ mice, 
the expression of oncogenic KrasG12D in pancreatic cells induced pancreatic intraepithelial 
neoplasia (PanIN) and PDAC (Schönhuber et al., 2014). The functional relevance of MCs in 
PDAC initiation and formation was studied in this mouse model. MC deficiency was generated 
by crossing CPA3 Cre/+ mice (a Cre-mediated eradication of the entire MC lineage 
(Feyerband et al: 2011)) with Pdx1-Flp;FSF-KrasG12D/+ mice. Transgenic Cpa3Cre/+ mice and 
Cpa3Cre- controls were analysed for MC contribution to pancreatic cancerogenesis. In the 
absence of MCs, no changes to the numbers of pancreatic intraepithelial neoplasia (PanIN) 
or to PDAC grade were observed between MC-proficient and deficient mice, suggesting that 
MCs are dispensable in pancreatic cancer. This is contradictory to previous reports of 
experiments using kit mutants (Schönhuber et al., 2014).  
Collectively, while kit mutant mast cell deficiency models suggested an important pro 
tumorigenic role of MCs in most but not all cancer models are analysed, findings based on 
the novel MC-deficient model CPA3 cre or Cre-master mice do not support this concept.  
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 Human papilloma virus in cancer 
Human papillomaviruses (HPVs) are small, double-stranded DNA viruses that are members 
of the Papovaviridae family. The HPV genome is composed of six early (E1, E2, E4, E5, E6, 
and E7) open reading frames (ORFs), two late (L1 and L2) ORFs, and a non-coding long 
control region (LCR). HPVs primarily infect and replicate in the basal layer of epithelia of the 
skin and mucosal surfaces. Early genes of HPVs are expressed at the onset of infection; the 
two primary onco-proteins of high-risk HPV types are the E6 and E7 proteins, which bind 
primarily to the two tumour suppressor proteins p53 (inactivated by E6) and pRb (inactivated 
by E7), altering cell cycle regulatory pathways (Gurish and Austen, 2012). This causes 
epithelial hyper proliferation that results in hyperplasia; this can progress to dysplasia and 
SCC (Arbeit et al., 1994; Smola, 2014). There are more than 100 different types of HPV, and 
persistent infection with high-risk, oncogenic HPV subtypes have been widely implicated in 
the development of cervical cancer due to the correlation of infections with high-grade cervical 
(epithelial) cell abnormalities. The HPV subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 68, 69, 73 and 82 are considered high risk. Among these, HPV16 accounts for 50% of 
cervical cancer cases (Muñoz  et al., 2003). Together, HPV16 and HPV18 account for 
approximately 70% of SCCs and adenocarcinomas of the cervix (Ringström et al., 2002). 
 
 Mast cells in HPV-induced cancer 
MCs are a predominant cell type in the local immune microenvironment of human HPV-
induced intraepithelial neoplasia. The number of MCs varies with different grades of neoplasia 
(Wilk et al., 2010). Mouse studies have suggested that MCs actively participate in remodelling 
tissue architecture, activating tumour neo-angiogenesis in HPV-induced neoplasia 
(Coussens et al., 1999). In a mouse model of epithelial carcinogenesis, K14-HPV16 mice, 
the early region genes of HPV16 are expressed under the control of the keratin 14 (K14) 
promoter/enhancer. In this HPV16-induced skin cancer model, mice are born phenotypically 
normal; however, by one month of age, the mice develop epidermal hyperplasia with 100% 
penetrance, which advances focally into angiogenic dysplasia between three and six months. 
By one year of age, 50% of the mice develop invasive SCCs (Arbeit et al., 1994; Coussens 
et al., 1999). Already in early stages of neoplasia, MCs were increased in numbers. Activation 
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of tumour neo-angiogenesis, the so called “angiogenic switch,” was accompanied by a 
marked increase in MC density in this model. In later lesions, the dysplastic stage, a dramatic 
increase in the expression of two MC-specific proteases, mMCP-6 (a tryptase) and mMCP-4 
(a chymase) was found. This suggests that MCs contribute to premalignant progression by 
remodelling the extracellular matrix and activating tumour neo-angiogenesis (Coussens et 
al., 1999). To test this hypothesis in vivo, Coussens et al crossed the MC-deficient KITW/W-v 
mice background on to the K14-HPV16 strain. As the neoplastic progression of K14-HPV16 
is permissive only in FVB/n, and as the WBB6F1 KITW/W-v mice are sterile, KITW/+ (WB/ReJ) 
and KITWv/+ (C57BL/6J) alleles were separately back crossed into FVB/n for four generations 
which inter crossed each W allele was intercrossed with K14–HPV16 on the FVB/n genetic 
background. To obtain K14–HPV16 KITW/Wv genotypes, HPV16 KITW/+ with KITWv/+ and 
HPV16 KITWv/+ with KITW/+ were crossed, resulting in the generation of 104 litters. From the 
712 live pups, 89 pups were predicted to be MC-deficient HPV16 transgenic mice. However, 
only one single pup was found with the desired K14–HPV16 KITW/W-v genotype that the 
KITW/W-v genotype produces a near-lethal phenotype on the FVB/n background. Analysis of 
the single MC-deficient K14-HPV16 transgenic offspring obtained showed low MC numbers 
as expected with a lower keratinocyte proliferation and a quiescent vasculature that was 
similar to that of the controls. This finding was suggestive of an important role of MCs in 
tumour biology and is frequently cited in this context. However, it is not clear whether the 
impaired tumour development in this single animal was due to lack of MCs or was caused by 
other effects of Kit deficiency of some other spontaneous mutation that rescued this particular 
animal from the lethal phenotype of the KITW/W-v genotype on the FVB/n background. 
Therefore, reinvestigation of the functional relevance of MCs in mouse models of epithelial 
cancers using a kit-independent MC-deficient mouse model is required.  
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  Objective 
Many human cancers accumulate high numbers of MCs in the tumor stroma. In some entities, 
numbers of MCs correlate with poor prognosis. Thus, it seems plausible that these cells could 
play an important role in tumor biology. Experiments in MC-deficient kit mutant mice showed 
that tumor formation and growth were reduced in the absence of mast cells. It was concluded 
that, MCs promote cancerogenesis and tumor growth. However, the interpretation of results 
obtained with these kit mutant strains has to take into consideration that any phenotype may 
not be caused by the absence of MCs but rather by additional alterations in the immune 
system or other organ systems resulting from reduced KIT function. Importantly, numerous 
key observation that were made in kit mutant MC-deficient mice over the past decades were 
not reproduced in novel, kit independent mouse models of MC deficiency. Therefore, it is 
important to reassess the role of MCs in tumor biology using kit-independent mouse models. 
The present study was conducted to clarify the role of mast cells in HPV-induced skin cancer 
by achieving the following aims. 
 
1. To establish mast cell deficiency in the K14-HPV16 mouse strain, a mouse model for 
squamous cell carcinoma (SCC) using a kit-independent, Cre/loxP-based mouse model of 
MC deficiency.  
 
2. To investigate the functions of MCs in early and late neoplasia stages by comparing 
parameters of tumor growth in MC-deficient versus MC-proficient mice.  
 
3. To determine the impact of mast cells on the immune cell infiltrate of the tumor stroma.  
 
4. To compare the progression to SCC in MC-deficient versus MC-proficient mice. 
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 Materials and methods 
 Materials 
2.1.1 Buffers 
Buffers Recipes 
1x Erythrocyte-lysis Buffer 155 mM NH4Cl 
10 mM KHCO3 
0.1 mM EDTA 
1x PBS 137 mM NaCl 
2.7 mM KCl 
10 mM NaH2PO4 
1.8 mM KH2PO4 
pH 7.4; autoclaved 
10x Loading dye 60 % Glycerol 
10 % 0.5 M EDTA 
30 % dH2O 
Bromphenol blue 
10x PCR-Buffer 750 mM TrisHCl; pH 8.8 
200 mM (NH4)2SO4 
20 mM MgCl2 
0.1 % Tween 20 
FACS-Buffer 1 x PBS 
2 % BSA 
Lysis Buffer 0.1 M Tris-HCl 
0.2 M NaCl 
0.2 % SDS 
5 mM EDTA 
pH 8.5 
0.1 mg/ml Proteinase K freshly added 
Antibody Blocking Buffer 1 % BSA 
0.1 % cold fish skin gelatin 
5 % Triton X-100 
0.05 % sodium azide 
0.01 M PBS, pH 7.2-7.4 
Hydrogen peroxide 
(H2O2) blocking Buffer 
30 % H2O2 
1x PBS 
Antibody dilution Buffer 
Primary/ Secondary 
1%BSA 
0.1 % cold fish skin gelatin 
0.5 % Triton X-100 
0.05 % sodium azide 
0.01 M PBS, pH7.2-7.4 
Sodium citrate Buffer 10 mM  Tri sodium citrate 
0.05 % Tween 20 
Adjust pH to 6.0 with HCl 
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Alkaline phosphatase Buffer 100 mM Tris-HCl 
100 mM NaCl 
50 mM MgCl2 
Adjust  pH to 9.5 
Proteinase K solution 0.06 U per ml 
TE buffer, pH 8.0 
Horse radish peroxidase (HRP)  
substrate solution 84 µl of Buffer stock 
100 µl  of DAB solution 
80 µl of H2O2 solution 
Permeabilisation Buffer 0.1 % Triton X 100 
0.1 % Sodium citrate 
 
 Commercial kits 
Kits Commercial source 
In Situ Cell Death Detection Kit, AP Roche Diagnostics GmbH, Mannheim 
GENECLEAN Turbo Kit MP Biomedicals GmbH, Eschwege 
RNeasy Micro Kit QIAGEN GmbH, Hilden 
DAB Substrate Kit Vector Laboratories, Burlingame, U.S.A 
 
2.2.1 Recombinant enzymes and proteins 
Enzymes / Proteins Commercial source 
LiberaseTM Roche Diagnostics GmbH, Mannheim 
DnaseI Roche Diagnostics GmbH, Mannheim 
Hyaluronidase Sigma-Aldrich Chemie GmbH, München 
Proteinase K Sigma-Aldrich Chemie GmbH, München 
RNase A Sigma-Aldrich Chemie GmbH, München 
Taq-Polymerase (pTaq Plasmid) Roche Diagnostics GmbH, Mannheim 
 
2.2.2 Primary and secondary antibodies 
Antibodies Clone Commercial source 
Rat anti-Mouse Ki-67 TEC-3 Dako Deutschland GmbH 
 
Biotinylated rabbit anti rat IgGs 
 
E0464 Dako Deutschland GmbH 
 
Streptavidin-HRP P 0397 Dako Deutschland GmbH 
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2.2.3 Oligonucleotides 
All PCR primers were purchased from Metabion 
No Oligonucleotide Sequence (5'→3') 
P1 K14HPV16 Fwd AGA ACT GCA ATG TTT CAG GAC CCA CAG 
P2 K14HPV16 Fwd TCT GCA ACA AGA CAT ACA TCG ACC GG 
P3 M5Cre Fwd ACA GTG GTA TTC CCG GGG AGT GT 
P4 M5Cre Rev1 GTC AGT GCG TTC AAA GGC CA 
P5 M5Cre Rev 2 TGA GAA GGG CTA TGA GTC CCA 
P6 RDTA Fwd AAA GTC GCT CTG AGT TGT TAT 
P7 RDTA Rev AAG AAC GGA GCC GGT TGG CG 
2.2.4  
2.2.5 Chemicals and reagents 
Chemicals / Reagents Commercial source 
Agarose Serva GmbH, Heidelberg 
Amino ethyl carbazol Sigma-Aldrich Chemie GmbH, München 
Ammonium chloride (NH4Cl) Merck KGaA, Darmstadt 
Ammonium per sulphate (APS) Sigma-Aldrich Chemie GmbH, München 
Ammonium sulphate ((NH4)2SO4) Sigma-Aldrich Chemie GmbH, München 
β-Mercapto ethanol Sigma-Aldrich Chemie GmbH, München 
Bromophenol Blue Sigma-Aldrich Chemie GmbH, München 
BSA (bovines Serum albumin) New England Biolabs GmbH, Frankfurt 
Calcium chloride-Dihydrate Sigma-Aldrich Chemie GmbH, München 
Chloroform Carl Roth GmbH & Co.KG, Karlsruhe 
Dithiothreitol (DTT) Sigma-Aldrich Chemie GmbH, München 
DMEM + GlutaMAX Life Technologies GmbH, Darmstadt 
DMSO (Dimethyl sulfoxide) Merck KGaA, Darmstadt 
dNTP-Set Thermo Scientific, Karlsruhe 
Mounting Medium EUROIMMUN AG, Lübeck 
Entellan Merck KGaA, Darmstadt 
Eosin Sigma-Aldrich Chemie GmbH, München 
Acetic Acid Merck KGaA, Darmstadt 
Ethanol, absolute VWR International GmbH, Darmstadt 
Ethidium bromide Sigma-Aldrich Chemie GmbH, München 
Ethylene diamin tetra acetate (EDTA) VWR International GmbH, Darmstadt 
Fetal calf serum (FCS) Biochrom AG, Berlin 
Formaldehyde solution (4 %) SAV LP, Flintsbach 
Gene Ruler 1 kb DNA Ladder Thermo Scientific, Karlsruhe 
Giemsa  Merck KGaA, Darmstadt 
Glycerin Biochrom AG, Berlin 
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Glycine Carl Roth GmbH & Co.KG, Karlsruhe 
HEPES Biochrom AG, Berlin 
Isofluran Baxter, Unterschleißheim 
Isopropanol VWR International GmbH, Darmstadt 
Potassium acetate Merck KGaA, Darmstadt 
Potassium chloride (KCl) Fluka Chemie GmbH, Buchs 
Potassium dihydrogen phosphate (KH2PO4) Merck KGaA, Darmstadt 
Potassium hydrogen carbonate (KHCO3) Merck KGaA, Darmstadt 
L-Alanyl L-Glutamine Biochrom AG, Berlin 
L-Glutamine Biochrom AG, Berlin 
Magnesium chloride (MgCl2) Merck KGaA, Darmstadt 
Mayers Haemotoxylin solution SAV LP, Flintsbach 
Methanol Merck KGaA, Darmstadt 
Sodium acetate Merck KGaA, Darmstadt 
Sodium chloride (NaCl) VWR International GmbH, Darmstadt 
Sodium dihydrogenphosphate (NaH2PO4) Merck KGaA, Darmstadt 
Sodiumhydroxide (NaOH) Carl Roth GmbH & Co.KG, Karlsruhe 
Non-essential amino acid (100x) Biochrom AG, Berlin 
NP-40 Sigma-Aldrich Chemie GmbH, München 
Paraplast® Sigma-Aldrich Chemie GmbH, München 
Penicillin Biochrom AG, Berlin 
Phenol-Chloroform-Isoamyl alcohol Carl Roth GmbH & Co.KG, Karlsruhe 
Propidium iodide (PI) Sigma-Aldrich Chemie GmbH, München 
RPMI 1640 Biochrom AG, Berlin 
Hydrochloric acid (HCl) VWR International GmbH, Darmstadt 
Sodium dodecyl sulphate (SDS) Carl Roth GmbH & Co.KG, Karlsruhe 
Sodium pyruvate Biochrom AG, Berlin 
Streptomycin Biochrom AG, Berlin 
Tri-sodium citrate-dihydrate VWR International GmbH, Darmstadt 
Tris Carl Roth GmbH & Co.KG, Karlsruhe 
Trypsin (10x) Life Technologies GmbH, Darmstadt 
Triton X 100 Sigma-Aldrich Chemie GmbH, München 
Tween 20 VWR International GmbH, Darmstadt 
Injection Water Serumwerk Bernburg AG, Bernburg 
Xylol VWR International GmbH, Darmstadt 
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2.2.6 Supplement materials 
Materials Commercial source 
Coverslips (24 x 60 mm) Süsse Labortechnik, Gudensberg 
Embedding Casettes Engelbrecht Medizin- und Labortechnik 
GmbH, Edermünde 
Disposable Pipettes Corning GmbH, Kaiserslautern 
Disposable Syringes Becton Dickinson, Heidelberg 
Disposable Needles (18G, 23 1/2G) Becton Dickinson, Heidelberg 
Micro-Haematocrit-capillaries, Heparinized Brand, Wertheim 
Microscope slides STAR FROST Knittel, Braunschweig 
PCR-tubes 0.2 ml Sarstedt AG & Co., Nürnbrecht 
Petridish Greiner Bio-One GmbH,Frickenhausen 
Pipette tips Eppendorf AG, Hamburg 
SafeSeal test tubes (1.5 ml, 2 ml) Sarstedt AG & Co., Nürnbrecht 
Sterile filter (0,2 μm) Corning GmbH, Kaiserslautern 
Whatmann Paper Whatman International, Maidstone, UK 
Cell culture flasks (T25, T75, T175) Greiner Bio-One GmbH, Frickenhausen 
SEFAR Nitex cell strainer 03-41/31 (40 μm) Sefar GmbH, Edling 
Centirfuge tubes (15 ml, 50 ml) Greiner Bio-One GmbH, Frickenhausen 
 
2.2.7 Instruments 
Instruments Company 
Axiocam Zeiss, Jena 
Axioskop Zeiss, Jena 
CO2-Incubator HERAcell 240i Thermo Scientific, Karlsruhe 
BD Facs Aria III Cell Sorter BD Biosciences, San Jose, USA 
BD LSR II FACS analzyer BD Biosciences, San Jose, USA 
MACSQuant Flow cztometry Miltenyi Biotec GmbH, Bergisch, Gladbach 
Elektrophoresis-Kammern Sub-Cell® GT Bio-Rad Laboratories GmbH, München 
Casting machine EG 1150 C Leica Microsystems Nussloch GmbH, 
Nussloch 
Inverse microskope ID 03 Zeiss, Jena 
Luminescent Image Analyzer LAS-3000 FUJIFILM Europe GmbH, Düsseldorf 
Molecular Imager® ChemiDoc™ XRS 
Imaging System 
Bio-Rad Laboratories GmbH, München 
NanoDrop® G. Kisker GbR, Steinfurt 
Neubauer counting chamber LO Laboroptik, Friedrichsdorf 
PCR-Cycler T 3000 Thermocycler Biometra Biomedizinische Analytik GmbH, 
Göttingen 
pH-Meter 763 Multi-Calimatic Knick Elektronische Messgeräte GmbH & 
Co. KG, Berlin 
23 
 
Pipettes Abimed GmbH, Langenfeld 
Rotary microtome RM 2265 Leica Microsystems Nussloch GmbH, 
Nussloch 
Rotatory-Vaccum-conctrator RVC 2-18 Martin Christ Gefriertrocknungsanlagen 
GmbH, Osterode am Harz 
Rotator Bachofer Laboratoriumsgeräte, Reutlingen 
Voltage equipment Power Pac™ Basic 
Power Supply 
Bio-Rad Laboratories GmbH, München 
Sterile bench Herasafe Typ HS18/2 Heraeus, Hanau 
Tissue Processor TP1020 Leica Microsystems Nussloch GmbH, 
Nussloch 
Thermo mixer comfort Eppendorf AG, Hamburg 
Ultrazentrifuge Beckman Optima LE-80K Beckman Coulter GmbH, Krefeld 
Water bath Medingen W12 P-D Industriegesellschaft, Dresden 
Centrifuge Heraeus Fresco 17 Thermo Scientific, Karlsruhe 
Centrifuge Rotina 420R Hettich, Tuttlingen 
 
2.2.8 Analysis software 
Software Company 
AxioVision Zeiss, Jena 
BD FACS DIVA BD Biosciences, San Jose, USA 
Image J NIH 
FlowJo V.7.6 Tree Star, Ashland, USA 
MACSQuantify Miltenyi Biotec GmbH, Bergisch 
 
 Mice 
2.3.1 Animal husbandry 
All animals used for this research were maintained under specified pathogen - free conditions 
at the Experimental Center, Medical Faculty Carl Gustav Carus, Dresden University of 
Technology. Mice were kept under standard climatic conditions with a room temperature of 
22°C and a relative humidity between 50 and 60 %. In a regulated day / night cycle every 12 
hours, a change of light and dark phase was performed. In an individually ventilated plastic 
cages (Type IIL) with a floor area of 540 cm2 and height of 12 cm, a breeding pair with litter 
or a maximum of five animals of one sex ever kept. The mice were given water and food ad 
libitum. The pups were separated at three weeks of age from their parent’s mice, marked with 
an ear tag and separated by gender. Genotyping of mice was performed by PCR or Southern 
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blot after a biopsy of the tail. The experiments with mice were performed according to the 
guidelines for animal welfare and approved by the State Directorate Dresden. 
 
2.3.2 Mouse Strains 
Following are the list of mouse lines that are used for this research. 
Table 2.1: Mouse lines with its respective genetic background 
Mouse lines Genetic background Reference 
RDTA BL6 (Voehringer et al., 2008) 
M5Cre BL6 (Scholten et al., 2008a) 
K14-HPV16 FVB/n (Arbeit et al., 1994) 
 
2.3.3 Generation of mouse lines in FVB/n genetic background 
Mcpt5-Cre and R-DTA mice were generated and maintained on C57BL6 genetic background. 
Prior to intercrossing with K14-HPV16 mice, R-DTA and Mcpt5-Cre mouse strains each were 
separately backcrossed with FVB/n mice for at least 5 generations. For backcrossing purpose 
always FVB/n (Janvier) female mouse were preferred as breeding female mouse. 
2.3.4 K14-HPV16 mice as squamous cell carcinoma mouse model 
(SCC) 
A mouse model for squamous cell carcinoma was generated by expressing the early region 
genes of human papilloma virus 16 (HPV16) under the control of human keratin 
promoter / enhancer in the basal keratinocytes. Mice were born phenotypically normal and 
by one month of age, the epidermises of the ears are consistently affected. Ears of these 
mice develop mild hyperplasia to hyperplasia followed by dysplasia. Papillomatosis of the 
eyelid and snout were 100% penetrant in this mouse line. Other anatomical sites that are 
affected by this transgene are truncal skin and anus. In spite of the frequency and consistent 
development of severe dysplasia, the K14/HPV16 mice were rarely developed squamous 
cancers. Genetic susceptibility is significant determinant in the conversion of HPV16 lesion 
into malignancies. C57BL6 mouse are resistant to the development of the epithelial cancer, 
Thus, K14-HPV16 mice are backcrossed to FVB/n inbred mouse line that develop squamous 
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cancers in the early backcross generations suggesting that this strain may be permissive for 
malignant progression of genetically induced epidermal lesions. Thus, FVB/n appears to 
contain a dominant susceptibility locus that contributes to malignant conversion. To retain the 
100% K14-HPV16 pathological phenotype, mouse lines that are generated in C57BL6 are 
backcrossed in FVB/n inbred mouse line prior intercrossing with this transgenic animal. 
 Molecular biology methods 
2.4.1 Isolation of genomic tail DNA 
Mouse tail tips, about 0.5 cm in length, were incubated overnight at 55°C rocking in 500 μl 
lysis buffer (200 mM TrisHCl, 100 mM NaCl, 1% SDS (w/v), 50 mM EDTA) supplemented 
with 100 μg Proteinase K (Fermentas Life Sciences). Undigested material was sedimented 
by centrifugation and the supernatant was collected in a fresh 1.5 ml microcentrifuge tube 
containing 500 μl isopropanol. The samples were mixed by inverting the tubes several times. 
The precipitated DNA was pelleted by centrifugation and washed once with 70% ethanol. The 
air dried DNA pellet was dissolved in TE buffer by incubating at 55°C shaking for at least 2 h. 
2.4.2 Isolation of total RNA 
The isolation of total RNA was performed using the RNeasy micro kit according to the 
manufacturer's instructions, with the protocol “Purification of Total RNA from Animal Cells 
Using Spin Technology" obtained from the Qiagen manual 01/2011. 
 
2.4.3 Quantification of DNA 
The concentration of DNA was determined by measuring absorption at 260 nm and 280 nm 
(A260 and A280). An A260 of 1 corresponds to a concentration of approximately 50 μg/ml of 
double stranded DNA. The purity of the DNA can be assessed by calculating the ratio of 
A260/A280 with 1.8 reflecting pure DNA. A ratio below or above 1.8 indicates protein or RNA 
contamination, respectively. Alternatively, DNA concentrations were estimated in an agarose 
gel after electrophoresis by comparing the band intensities with a standard.  
26 
 
2.4.4 Polymerase chain reaction 
The polymerase chain reaction (PCR) was used for various applications like the probe 
synthesis, genotyping. In a standard protocol 10-100 ng template DNA was amplified with 1x 
reaction buffer, 2 mM MgCl2, 200 nM each primer, 200 μM dNTP mix and 0.05 U/μl Taq-
Polymerase were used (Fermentas Life Sciences except primers). For most applications the 
template DNA was denatured at 95°C for 5 min followed by 30-35 cycles of 45 secs at 95°C, 
1 min at the appropriate annealing temperature and 1 min per kb DNA to be amplified at 
synthesis temperature (72°C). Amplification was completed with a final synthesis step at 72°C 
for 7 min. The optimal annealing temperature of the primers was estimated with the following 
formula: TA=59.9+0.41(GC%)-600/L (GC%, GC content in percent, L, total number of base 
pairs). 34 μl of the PCR mastermix were added, samples were mixed by tapping and further 
processed as described below. 
2.4.4.1 Standard PCR 
Mice were genotyped by standard PCR as specified below. Primers are purchased from 
metabion and primer sequence are described in section 2.2.3 
Table 2.2: Table displays PCR conditions and expected DNA fragments for different mouse lines 
Typing Primer Nos tA / No of Cycles Products 
K14-HPV16 P1/P2 Touch down pgm TG+ 400bp, wt - 
M5Cre P3/P4/P5 Touch down pgm Cre- 600bp 
RDTA P6/P7 Touch down pgm 300bp 
 
Table 2.3: Touch down program 
Temperature in °C Time No of Cycles 
95 4 min  
94 30 secs  
60 30 secs 2 cycles 
72 45 secs  
94 30 secs  
58 30 secs 2 cycles 
72 45 secs  
94 30 secs  
56 30 secs 2 cycles 
72 45 secs  
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94 30 secs  
54 30 secs 34 cycles 
72 45 secs  
72 10 min  
15 pause  
 
For genotyping the other mouse lines, a so-called touchdown program was adopted in which 
a high annealing temperature in this PCR was applied at initial cycles, resulting in binding of 
primers to the DNA with high specificity and the annealing temperature for subsequent cycles 
are gradually reduced. 
2.4.5 Illumina based differential gene expression analysis 
CD45+ immune cells were flow-cytometrically sorted from ear skin of K14-HPV16+ 
RDTA+/+M5Cre- and M5Cre+ mice and lysed immediately in Qiagen RNA Isolation Kit lysis 
buffer (Qiagen). RNA samples were sequenced at Deep sequencing facility, CRTD, Dresden. 
 Flow Cytometry Analysis 
2.5.1 Preparation of cell suspensions and FACS analysis 
2.5.1.1 Peritoneal cell suspension 
Mice were sacrificed; the abdominal skin was carefully removed without damaging the 
peritoneum. A small incision in peritonium was made with sterile scissor and peritoneal cavity 
was flushed with 4-8 mL of ice cold PBS Cells were sedimented and the pellet re-suspended 
in FACS buffer. 
2.5.1.2 Ear skin suspension 
For preparation of skin cell suspensions, untagged ear skin tissue was excised and cut into 
small pieces using scalpels, followed by a 30 minutes enzymatic digestion in 1mL DMEM 
containing 20 mM Hepes, 0.025 mg/ml Liberase TM, 396 U/ml DNase I, and 0.5 mg/ml 
Hyaluronidase at 37°C, 1400 rpm in thermo mixer. Excessive digestion was stopped by 
adding DMEM containing 10% FBS (Invitrogen) and filtered through a 40-μm mesh (SEFAR 
NITEX) and cell suspension was washed twice with PBS. 
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2.5.1.3 Single cell suspension from other tissues 
Cells isolated from skin, spleen, bone marrow or blood was re suspended in PBS/2% BSA. 
2-5x105 cells were stained with monoclonal antibodies (Table 2.4) in 100μl staining solution 
for 30’ at 4°C. Cell suspensions were washed twice and were re suspended in 200μl PBS/2% 
BSA. To determine cell viability, 1μg/mL Propidium iodide was added. Analysis was done 
using the LSR II instrument and Flowjo software was used to analyze the fcs files. 
2.5.2 Surface marker staining 
The hematopoietic cells in the cell suspensions (described below) were identified by staining 
for cell surface markers. Unspecific binding of antibodies to Fc receptors via their invariable 
part of the heavy chain was avoided by blocking with anti-CD16/32 (eBioscience) directed 
against the FcIII and the FcII receptor, respectively. Subsequently, cells were incubated 
with the antibodies (listed in table) 50-100μl FACS buffer for 30 min on ice. After two washing 
steps propidium iodide was added (final concentration 0.5 μg/ml) for the detection of dead 
cells. The samples were analyzed in a BD LSR II or MACS Quant analyzer. 
Table 2.4: Monoclonal antibodies and their final dilution used in flow cytometry 
Specificity Clone Flourochrome Dilution 
Commercial 
source 
CD117 2B8 APC 1:500 eBioscience 
CD11b M1/70 FITC 1:800 eBioscience 
CD11c N418 APC 1:500 BioLegend 
CD19 eBio1D3 (1D3) FITC 1:400 eBioscience 
CD4 GK1.5 PE 1:400 eBioscience 
CD45 30-F11 eFlour450 1:500 eBioscience 
CD49b DX5 PeCy7 1:400 eBioscience 
CD8a 53-6.7 PeCy7 1:400 eBioscience 
CD3e eBio500A2 APCeflour780 1:400 eBioscience 
F480 BM8 APC 1:400 eBioscience 
FcepsilonR1alpha Mar-01 PE 1:300 eBioscience 
GR1 RB6-8C5 PerCp Cy5.5 1.400 eBioscience 
MHCII IAB AF6-120.1 PeCy7 1.200 BioLegend 
NK1.1 PK136 APC 1:200 eBioscience 
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2.5.3 Sorting  
2.5.3.1 CD45+ cells sorting 
Ear skin from mast cell proficient and deficient tumour tissue at 2 and 6 months old mice was 
excised and digested as described in the section 2.5.1.2. In brief, unspecific binding of 
antibodies to Fc receptors via their invariable part of the heavy chain was avoided by blocking 
with anti-CD16/32 (eBioscience) directed against the FcIII and the FcII receptor, 
respectively. After two washes with FACS buffer, the cells were further processed for surface 
markers staining. Characteristic surface markers used to identify the specific cell type are 
listed in the Table 2.5. CD45+ cells with and without mast cells in the mast cell proficient and 
deficient tumor tissue was sorted in 15ml falcon tubes containing 350 μl RLT buffer (Qiagen). 
The cell lysate was immediately stored at -80°C until further process.  
Table 2.5: Characteristics surface markers for hematopoietic cell sorting 
Cell type Surface marker 
Hematopoietic cells  CD45 
Mast cells Ckit, Fcepsilon R1alpha 
 
 Histology 
2.6.1 Animal sacrifice 
Mice were sacrificed as per the guidelines of Experimental centre, MTZ, TU Dresden. 
Euthanasia was achieved either by cervical dislocation, decapitation or by inhalation of 
isoflurane an anaesthetic agent. Mouse tissues were excised immediately and processed for 
either cryo preservation or paraffin embedding procedures as described below. Animal 
carcass was either stored in 4% formalin or discarded as per the GMO guidelines. 
2.6.2 Animal tissue processing for paraffin embedded sections 
Animals were sacrificed as described above and tissues were excised and fixed with 4% 
Formaldehyde overnight and dehydration carried out by washing tissues with series of alcohol 
and rehydrate in Tissue Processor TP1020 and preserved with paraffin. 5 µM thick tissue 
sections were cut using Rotary microtome RM 2265 and processed for further staining. 
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2.6.3 Animal tissue processing for Cryo mold sections 
Mouse tissue were excised and cryo molds were prepared with sakura tissue tek OCT 
medium and stored at -80°C. 5 µM thick frozen sections were prepared using Cryostat and 
processed for further immune stainings. 
2.6.4 Haematoxylin & Eosin Staining / Epidermal thickness 
measurement 
Mayer’s haematoxylin staining was used for morphological evaluation and as a counterstain 
in immunohistochemistry procedures. 5 µM thick paraffin embedded tissue sections were 
heat fixed at 56 °C for 30 minutes and processed further for alcohol washes. Slides were 
dipped in Haematoxylin solution and excess dye washed in running tap water and counter 
stained with Eosin dye. Haematoxylin/Eosin stains cell nuclei blue and cell cytoplasm red 
respectively. Epidermal thickness was quantified by measuring the epidermal area in pixels 
(based on the blue staining using an image analysis program) of all tissue sections.  
2.6.5 Quantification of mast cells with Giemsa 
Mast cells were identified with Giemsa staining by means of their dark purple cytoplasmic 
granules. In ear skin sections mast cells appeared dark purple and were localized between 
epithelial cells Mast cells were quantified as cells/mm derma length at a final magnification of 
200x. 
2.6.6 TUNEL Assay 
Terminal-deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling (TUNEL) assays 
were performed to quantitate the level of apoptosis occurred in mast cell proficient and 
deficient tumor tissues at different time points. 5 μM thick tissue sections were deparaffinized 
and rehydrated with ethanol washes as described in Section 2.6.2. Tissue sections are 
subjected to antigen retrieval process by heating in 0.1M Sodium citrate buffer for 2 min and 
incubated with 2mg/ml Proteinase K solution at room temperature for 2 min. After washing 
the tissue sections with PBS thrice, 90 μL (1:1 dilution with PBS) of TdT enzyme mix applied 
to the sections and incubated at 37°C for one hour. Color development was achieved with 
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converter POD and number of DAB positive (brown color) cells were counted per mm dermal 
length. 4-week old mouse thymus sections were included as positive control for this staining. 
 
2.6.7 Determination of keratinocyte proliferation by Ki-67 Staining 
5-μm thick paraffin sections of ear skin tissues were deparaffinized in xylene, rehydrated in 
graded ethanol, and subjected to antigen retrieval by steam heating in 0.1M sodium citrate 
buffer PH 6.0. Tissue sections are incubated with H2O2 blocking buffer for 20 mins at room 
temperature. Following the blocking buffer, sections are incubated with Rat anti mouse Ki-67 
antibody. Antibody and substrate solution dilutions are listed in the section 2.2.2. Brown color 
positive cells are counted. Quantification of Ki-67+ cells determined as % Ki67+ cells. At least 
5 focal view per mouse was analyzed. 
Table 2.6: Immunohistochemistry conditions for Ki-67 Antigen 
Anitbody / Reagents Dilutions 
Rat anit mouse Ki/67  1:50 
Biotinylated rabbit anti rat IgGs 1:200 
Strepatavidin HRP 1:300 
DAB substrate solution 400μL per section (slide) 
 
 Statistics 
Statistical analyses were performed using Student’s t test (for two groups) with GraphPad Prism 
(Version 5.04) software (GraphPad Software Inc., San Diego, CA, USA). A P value of less than 
0.05 was considered statistically significant. Tumor incidence data were analyzed as Kaplan-
Meier curves. 
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 Results 
 Breeding a kit-independent mouse model of constitutive 
mast cell deficiency onto K14-HPV16 transgenic mice 
The two most commonly used mouse models for the investigation of mast cell in vivo 
functions are the KITW/Wv and KIT/Wsh mouse line (Galli et al., 2008b). Both mouse strains are 
impaired in their expression of the KIT gene (CD117), resulting in altered development of all 
hematopoietic subsets (Katz and Austen, 2011), which limits the interpretations of the 
outcome of experimental studies. Besides, reinvestigating the tumour promoting role of mast 
cells with Kit-independent MC mouse models in various mouse tumour models had a 
contradictory outcome. Therefore, our group has generated a mouse model for mast cell 
deficiency using Cre-loxp technology. Crossing of a M5Cre mouse line that expresses the 
Cre enzyme (cyclic recombinase) under the control of the mast cell-specific protease 5 (M5) 
promoter (Scholten et al., 2008b) with the R-DTA mouse line (Voehringer et al., 2008) which 
expresses diphtheria toxin A (DTA) under control of the ROSA26 promoter only after a loxP-
flanked stop cassette was excised by Cre allows a selective and efficient depletion of 
connective tissue type mast cells in vivo (Figure 3.1a). Cre-mediated recombination resulted 
in diphtheria toxin-mediated cell ablation in vivo (Voehringer et al., 2008). This mouse model 
will be ideal for the investigation of functions of mast cells in carcinogenesis and tumour 
growth. 
3.1.1 Ablation of peritoneal mast cells in RDTA x M5Cre mice 
In order to investigate the depletion of mast cells in vivo in RDTA-M5Cre mice, M5Cre positive 
and Cre-negative control mice were subjected to peritoneal lavage. The collected lavage fluid 
cells were analyzed for the presence of mast cells by flow cytometry. 
Mast cells were identified as cells positive for the surface markers c-kit (CD117) and FcεR1ɑ. 
In the RDTA x M5Cre negative mice, normal numbers of CD117+ FCεR1ɑ+ cells could be 
detected (1.33%±0.44 of total peritoneal cells, n=5), whereas in the RDTA +/+, M5Cre+ 
animals, the total number of mast cells in the peritoneal cavity were only 0.029%±0.014 n=5, 
equivalent to more than 97% depletion of mast cells compared to control (n=5, Figure 3.1 c 
and d). This depletion efficiency was similar to that of conventional kit mutant(s) mouse 
models of mast cell deficiency (Waskow et al., 2004). 
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In order to exclude that mast cells were present but lack the expression of mast cell surface 
markers in M5Cre positive mice, cytospins of the peritoneal aspirations were subjected for 
May-Grunwald Giemsa stain. Again, mast cells were absent in the RDTA M5Cre positive 
    
Figure 3.1: Efficient and selective depletion of peritoneal mast cells in RDTA M5Cre mice. (A) Schematic 
overview of the M5Cre and RDTA mouse line used to ablate mast cells invivo. In M5Cre R-DTA mice, 
Cre-recombinase is selectively expressed in mature MCs and excises a stop-element of the R-DTA 
knock in allele resulting in de-repression of suicidal diphtheria toxin expression. Dot plots of peritoneal 
cavity cells from RDTA+/+ M5Cre- (B, left) and RDTA+/+, M5Cre+ (C, left) mice were analyzed by flow 
cytometry gated on live cells for the presence of c-Kit+FcεRI+ mast cells (gated regions in A and B and 
in cytospins. The insert (B, right) shows a 2.5 times magnification of the neighboring mast cell. Scale 
bar represents 20 μm (d) Mean MC numbers ± SD of M5Cre+ R-DTA+/+ mice and Cre- controls 
determined by FACS analysis (e) Peritoneal immune cell subsets determined by FACS. n = 5 per group; 
Error bars represents mean ± SD. t-test was used to calculate significance. ns- not significant. 
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cytospins (Figure 3.1c) whereas morphologically mature mast cells were detected in M5Cre 
minus cytospins (Figure 3.1b).  
Other cell types present in the peritoneal cavity including macrophages, neutrophils and B 
cells were also quantified by flow cytometry. Macrophages were defined as F4/80+ cells, B 
cells were defined as CD19+ and neutrophils were defined as CD11b+ GR1+ cells. All the three 
cell subsets were unaffected by mast cell depletion in M5Cre positive mice (Figure 3.1e). 
These results demonstrate that mast cells in the peritoneal cavity were selectively depleted 
in RDTA-M5Cre mice. 
3.1.2 Ablation of mast cells in skin of RDTA x M5Cre mice 
MC numbers were also quantified in the skin, a second predominant anatomical site of 
location for connective tissue mast cells (CTMC). Single cell suspensions of ear skin were 
generated by enzymatic digest (section 2.5.1.2) from RDTA-M5Cre positive and Cre-negative 
control mice and analyzed by flow cytometry.  
CD45 leucocyte marker was used to exclude non-hematopoietic cells and mast cells were 
detected in the CD45+ population as CD45+CD117+FCεR1ɑ+ cells. In Cre-negative controls 
7.5%±0.8 (n=4) mast cells were detected, while of total CD45+ve cells (Figure 3.2 a and c), 
whereas in M5Cre positive animals, the total number of mast cells were only 0.72%±0.2 n=4, 
reflecting more than 96% depletion (n=4, Figure 3.2 b and d) reflecting the successful ablation 
of CD117+ FCεR1ɑ+ cells in ear skin. 
Next, mast cells depletion also assessed in the histological sections of the ear skin. MCs were 
stained dark purple by metachromatic Giemsa staining. Mast cells were quantified as the total 
number of mast cells per mm length of auricular cartilage. The average number of mast cells 
was about 59/mm in Cre minus controls whereas sections from M5Cre positive mice were 
completely devoid of mast cells reflecting almost 100% depletion efficiency. 
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3.1.3 Ablation of mast cells in abdominal, back and tail base skin of 
RDTA M5Cre mice 
Skin mast cells numbers vary with different anatomical sites (Janssens et al., 2005), 
therefore, skin of different anatomical sites of RDTA M5Cre mice was analysed histologically 
for the efficiency of mast cell depletion.  
Back skin of RDTA M5Cre mice contained an average number of mast cells of 0.3±0.2/mm 
(n=7) compared to 19.5±3.4 /mm in control mice (n=7, Figure 3.3 a and b). This represents a 
depletion efficiency of 99%. 
 
Figure 3.2: Ablation of mast cells in ear skin of RDTA M5Cre mice. Flow cytometric analysis of single 
cell suspensions from ear skin of RDTA+/+ M5Cre- (A, left) and RDTA+/+ M5Cre+ (B, left) mice were 
analyzed by flow cytometry gated on CD45+ cells for the presence of c-Kit+FcεRI+ mast cells (gated 
regions in A and B). Giemsa stained ear skin tissue sections of RDTA+/+ M5Cre+ and M5Cre- mice for 
identification of metachromatic mast cells. Scale bars represents 50μm (c) Mean ear skin MC numbers 
± SD of M5Cre+ R-DTA+/+ mice and Cre- controls determined by FACS analysis (d) Ear skin 
hematopoietic cell subsets were determined by FACS. n = 5 / group, Error bars represents mean ± SD. 
t-test was used to calculate significance. (e) Quantification of ear skin mast by histology. Numbers were 
mast cells/mm length of auricular cartilage are represented. 
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In abdominal skin, the mast cell depletion was comparable to back skin with 0.6±0.3 residual 
mast cells/mm (n=7, Figure 3.3 c and d) reflecting a depletion efficiency of almost 97% 
compared to that of controls (17.0±2.7 mast cells/mm, n=7). 
 
Figure 3.3: Ablation of cutaneous mast cells in back, abdominal and tail base skin as demonstrated in 
Giemsa-stained paraffin sections. (a) Back skin of control and RDTA M5Cre mice are shown. Black 
arrows indicate the Giemsa stain positive MCs. (C) MCs in the abdominal skin and (e) tail base skin (B) 
Total number of mast cells were quantified as mast cells/mm dermal length. White bars represent control 
mice (n=7), black bars represent RDTA M5Cre double positive mice (n=7). Scale bar represents 50μm. 
Error bar represents mean ± SD. t-test was used to calculate significance. P value ** 0.0036 *** < 0.0001. 
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Tail base skin of control animals had 21.2±1.5 mast cells/mm, n=7 (Figure 3.3 e and f). The 
average number of mast cells in this tissue was 3-fold lower than that of ear skin. However, 
the depletion efficiency was about 99%. Thus, these results suggest that Cre mediated 
ablation was efficient and consistent among different anatomical sites in RDTA M5Cre mice. 
3.1.4 Assessment of haematological parameters in mast cell-deficient 
RDTA M5Cre mice. 
In order to investigate whether mast cell depletion affected also other hematopoietic cell types 
in RDTA +/+, M5Cre mice, peripheral blood was collected from 6-8 week old mice and various 
hematological parameters were quantified using the Sysmex blood analyzer. No significant 
changes were detected in the total white blood cells counts of RDTA M5Cre positive mice 
compared to the control groups. The average number of WBC in RDTA M5Cre positive mice 
was 7889±755 /μl, n=7 compared to control group (7633±817 /μl (Figure 3.4a)) 
Thrombocytosis, was observed in KitW-sh/W-sh mutants (Nigrovic et al., 2008a). To test whether 
this phenotype can also be seen in RDTA M5Cre mice, platelets numbers were analyzed. No 
thrombocytosis was observed in M5Cre positive mice. The average number of platelets cells 
in M5Cre positive mice was (1205±74.47) x 103/μl, n=7 compared to (1303±55.85) 103/μl, n=6 
(Figure 3.4b)) in the controls.  
 
Basophils were significantly reduced in other Cre-loxP based MC-deficient mouse models 
(Gurish and Austen, 2012; Lilla et al., 2011b). Therefore, leucocyte subsets in the peripheral 
blood of RDTA M5cre mice were examined. The mean percentage of total lymphocytes in 
M5Cre positive was 76.91%±1.89, n=7 compared to control mice (71.55%±3.74, n=6 
(Figure 3.4c)). Basophil count were found similar in both groups. M5Cre+ mice group 
accounted for 0.285%±0.18, n=7 whereas M5Cre- controls groups also reflected a similar 
levels (0.166%%±0.16, n=6) of basophils. Likewise, no significant changes in eosinophils and 
neutrophils were observed (Figure 3.4 d and f respectively). Thus, these results suggest that 
Cre recombinase expression in our M5Cre RDTA model, unlike other Cre-loxP based MC 
deficiency models (Gurish and Austen, 2012; Lilla et al., 2011b) was restricted to mast cells. 
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In order to test whether our mast cell deficient mouse model harbors any red cell 
abnormalities, reticulocytes, RBC count, RBC distribution width, mean corpuscular volume, 
hematocrit and hemoglobin levels were measured.  
 
 
 
 
Figure 3.4: Leucocyte parameters of RDTA M5Cre mice. 
Peripheral blood from RDTA M5Cre- controls (closed circles) 
and RDTA M5Cre+ (open squares) mice were analyzed for 
(a) total white blood cells (b) platelets (C) percentage of 
lymphocytes (d) eosinophils (e) basophils (f) neutrophils and 
(g) monocytes. Values are mean. N=6 (M5Cre-) and 7 
(M5Cre+), none of the values differ significantly between the 
groups. t-test was used to calculate significance. 
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First reticulocyte count was determined, as it is a quantitative measure of bone marrow’s 
production of new blood cells. The mean reticulocyte count in M5Cre positive mice was about 
3942±245.2 x 102 cells/μl, n=7, (Figure 3.5b), similar to the control groups (3453±303.1 102 
cells/μl, n=6) suggesting that the bone marrow’s production of new blood cells was unaltered 
in mast cell-deficient mice. 
 
Figure 3.5: Red blood cell parameters of RDTA M5Cre mice. Peripheral blood from RDTA M5Cre- 
(closed circles) and RDTA M5Cre+ (open squares) mice was analyzed for red cell parameters (a) Total 
(RBC) red blood cells count(b) Reticulocyte count (C) Mean corpuscular volume MCV (d) Red blood 
cell distribution width (e) Hematocrit and (f) Hemoglobin levels. Values are mean. n=6 (M5Cre-) and 7 
(M5Cre+), none of the values differ significantly. t-test was used to calculate significance. 
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No significant difference was observed in the mean total number of red blood cells (RBC 
count) in M5Cre positive mice (967±24.42 x104 cells /μl, n=7 vs 990.3±16.24, n=6, 
(Figure 3.5a)) compared to the controls. Next, the size of the red blood cells was determined 
with mean corpuscle value (MCV) and RBC distribution width (Figure 3.5 c & d respectively). 
The RDTA M5Cre mice had mean hematocrit (hct) values of 45.76%±1.11, n=7, (Figure 3.5e) 
compared to 46.67%±0.78, n=6 of Cre-negative control mice and KitW/Wv mice (39% HCT, 
Chervenic et al. 1969). The average hemoglobin levels of the RDTA M5Cre mice was 
8.486±0.19 mmol/l, n =7,Figure 3.5 f) was similar to the control levels (8.767±0.1520 mmol/l 
n=6). In summary, no red blood cell abnormalities were detected in RDTA M5Cre mice. 
3.1.5 Normal ear skin blood vessel morphology in mast cell-deficient 
mice. 
Mast cells reside in the connective tissue and are often found near blood vessels that facilitate 
its products to act directly on endothelial cells. It has been shown that mast cell-derived 
heparin stimulates endothelial migration (Aziz Khan et al.1998) and blood vessel tube 
formation in vitro induced by mast cell-specific mediators for e.g., Mast cell specific tryptase 
(Blair RJ et al, 1997). In order to test whether the mast cell deficiency in RDTA M5Cre mice 
alters blood vessel development, CD31+ blood vessels were evaluated in RDTA M5Cre 
positive as well as M5Cre negative mice. 
Blood vessels were detected with CD31, also known as platelet endothelial adhesion 
molecule (PECAM-1), is a type I integral membrane glycoprotein and a member of the 
immunoglobulin super family of cell surface receptors. It is strongly expressed by all 
endothelial cells. Blood vessels (brown colored, (Figure 3.6a)) were counted as total number 
of CD31+ve structures per field of view (FOV). The average number of CD31+ve structures 
in control group was about 23.3±0.9 /FOV compared to 24.1±1.59 /FOV in mast cell deficient 
mice (Figure 3.6b). Thus, these observations suggest that mast cell deficiency in RDTA 
M5Cre does not interfere with blood vessel architecture. 
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In conclusion, the Cre-lox-P system in RDTA M5Cre allows efficient ablation of mast cells in 
the peritoneal cavity and skin without affecting other hematopoietic subsets. This new Kit 
independent mast cell-deficient mouse model was therefore ideally suited to analyze cancer 
development of K14-HPV mice in the absence of MCs. 
 
3.1.6 Generation of mast cell deficiency in HPV16 induced neoplasia 
Mast cells accumulate in high numbers in various human cancer tissues. This phenomenon 
is also observed in HPV16-induced epithelial lesions (Gavrieli, 1992). Similar phenotype was 
observed in the K14-HPV16 transgenic mouse model of multistage epithelial carcinogenesis 
(Coussens et al., 1999). 
The earliest pathological changes in K14-HPV16 mice occur from 1 month onwards. Ear skin 
epidermis develops hyperplasia with a 100% penetrance (Arbeit et al., 1994). This 
hyperplastic skin advances focally into hyper proliferative dysplastic lesions in 100% of mice 
aged 4-6 months. By one year, 50-60 % of mice develop squamous cell carcinoma (Arbeit et 
 
Figure 3.6: Blood vessels morphology unaltered in RDTA M5Cre mice. (a) 5 μM thick cryosections of 
ear skin of RDTA M5Cre+ and M5Cre- mice were stained for blood vessels with CD31 marker. Black 
and red arrows indicate blood vessels in the upper dermis and lower dermis respectively. (b) 
Quantification of CD31 positive structures was done by counting no of CD31 positive (brown staining) 
in 5 different fields of vision/mouse. n=3 / group. Scale bar represents 50μm C- Cartilage. Error bar 
represents mean±SD. t-test was used to calculate significance. ns- not significant. 
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al., 1994; Coussens et al., 1999). This characteristic phenotype was retained in our K14-
HPV16+RDTA+/+M5Cre+ and M5Cre- control mice. 
In order to investigate the depletion efficiency of mast cells in vivo in K14HPV16 RDTA-M5Cre 
mice, MCs per mm length of auricular cartilage were counted in Giemsa stained tissue 
sections (Figure 3.2). The average number of mast cells in the wild type ear skin was 45.4 ± 
9.7 no of mast cells / mm length of auricular cartilage, n=3 (Figure 3.2). In K14-
HPV16+RDTA+/+ mice, there is a three-fold increase in mast cells at 2 months (121.4 ± 9.8, 
n=3, Figure 3.7). At 6 months, the mean number of mast cells was increased to eight-fold 
(363.4 ± 39.36, n=5, Dysplasia, 6 months, see Figure 3.7) compared to normal skin.  
By one year, the mean number of mast cells raised to 535.2 ± 22.95 per mm, n=4 (Figure 
3.7), representing 12-fold increase compared to control skin. In contrast to other tumour 
models (Schönhuber et al., 2014; Soucek et al., 2007) where the mast cell density remains 
constant, mast cells numbers continuously increase in parallel with disease progression in 
K14-HPV16 mice.  
In K14-HPV16+RDTA+/+M5Cre+ ear skin tissue sections, virtually no mast cells were 
detectable with giemsa staining (0.3 ± 0.3, n=3, (Figure 3.7b) at the stage of hyperplasia, i.e., 
by 2 months. MC numbers were still low at the dysplastic stage (0.8 ± 0.8, n=5, Figure 3.7b)). 
This depletion persisted also at one year of age in K14-HPV16+RDTA+/+M5Cre+ mice (4.6 ± 
4.6, n=3; (Figure 3.7b)), showing that mast cells are constitutively depleted throughout 
disease progression.  
3.1.7 Homozygosity of RDTA allele results in efficient depletion of mast 
cells in SCC mouse model 
In contrast to the near complete mast cell deficiency in K14-HPV16RDTA M5Cre mice 
homozygous for the RDTA allele, occasional clonal expansions of mast cells are observed in 
the otherwise mast cell-deficient tissue environment, in animals heterozygous for the RDTA 
allele (Figure 3.8 a and b). These focal accumulations of mast cells most likely represent  
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clonal outgrowth of a single cell that escaped Cre-mediated mast cell depletion. These results 
confirm previous reports using other Cre mouse models with constitutive depletion by RDTA 
(Voehringer et al., 2008) or inducible depletion by iDTR cassette (Buch et al., 2005) where 
some Cre expressing cells are resistant to Cre-mediated recombination. Figure 3.8-C1 shows 
a typical mast-cell colony observed in K14-HPV16+ M5Cre+ RDTA mice (6-10 months). At 
young age, the number of mast cell colonies / cm of tissue length was 2 ± 1.5, n=3 mice, with 
an average number of mast cells per colony of 36.1 ± 17.2 (n=6 colonies were analyzed). 
 
Figure 3.7: Efficient and selective depletion of mast cells in HPV16-induced neoplasia. (A) 
Representative images of Giemsa–stained metachromatic mast cells (purple) in K14-HPV16 induced 
ear skin of RDTA +/+, M5Cre+ and M5Cre negative ctrls  at indicated age. (n = 3 animals per genotype). 
(B) Quantification of mast cells in K14-HPV16 RDTA +/+, M5Cre+ and M5Cre – ctrls. Mean ± SD.; 
Mast cells counted up to 5 mm of tissue/per animal. SD. t-test was used to calculate significance. P 
value ****< 0.0001. Dotted red basement membrane; e, epidermis; d, dermis. Scale bars represent 50 
μm.  
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In older animals, aged about 6-10 months, the number of MC colonies raised up to ≈ 5 
colonies per cm tissue length, n=6 mice, (Figure 3.9a) reflecting a 2.5-fold increase of MC 
colonies compared to young mice. Similarly, a 2-fold increase in MC numbers per colony 
(56.6 ± 8.4, n=105 colonies) was observed. In K14-HPV16+ M5Cre+RDTA homozygous 
tissue sections, the mast cell depletion was almost 100%, with very low numbers of new 
recurring MC colonies in both the young (≤ 1 colony per cm tissue length, n=3) and older mice 
 
Figure 3.8: Spontaneous reappearance of MC colonies in MC-deficient tumour environment. 
(A) Example of a rare local mast cell accumulation in RDTA homozygous K14-HPV16+, M5Cre+ mice.  
C1- Colony. Scale bar 200uM. 
 
 
Figure 3.9: Quantification of mast cell colonies in skin of RDTA homozygous and heterozygous K14-
HPV16 mice. (A) Total number of colonies per cm length of epithelium in young and old mice. Older 
mice homozygous for the RDTA allele only sporadically feature mast cell colonies. These rare colonies 
contained only few mast cells (B). No of mast cell per single colony counted in RDTA heterozygous and 
homozygous mice. P value < 0.0001. 
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group (≤ 1 colony per cm tissue length, n=6 mice) was observed. Moreover, the rare colonies 
observed in these mice were small and contained only few mast cells. Thus, homozygosity 
for the RDTA allele resulted in efficient depletion of mast cells. Very few spontaneously 
recurring MC colonies are negligible. 
 Mast cells in HPV16-induced neoplasia 
We now asked in what way the absence of mast cells impacted on tumour development. 
Given the, reappearance of spontaneous MC colonies in K14-HPV16+RDTA-/+ M5Cre+ 
mice, K14-HPV16 transgenic mice that were homozygous for the RDTA allele were used for 
this analysis. To investigate the effect of mast cells in neoplastic progression, K14-
HPV16+RDTA+/+M5Cre- and M5Cre+ animals were analyzed on at least two different 
stages, namely early and late neoplastic stage. 
3.2.1 Kinetics of epidermal hyperplasia and dysplasia in K14-HPV16 
transgenic mice are not altered in the absence of mast cells 
Ear skin consist of two layers, dermis and epidermis. The epidermis is separated from the 
dermis the basement membrane. The basal layer of the epidermis contains stem cells which 
self-renew and give rise to differentiated keratinocytes that migrate to the upper layer stratum 
spinosum, where they undergo morphological changes that results in their loss of nuclei and 
cytoplasm in stratum granulosum. These granule cells migrate to the outermost layer to form 
stratum corneum that is composed of a nucleated flattened (flakes) cells. 
Wild type mouse ear skin, the epidermis consists of only one or two cell layers of 
keratinocytes. In the transformed ear skin of K14-HPV16+ or K14-HPV16+ RDTA M5Cre 
negative control mice, the basal and granular layers of the epidermis were expanded to 2-4 
cells thickness with enlarged keratinocytes at 2 months (Arbeit et al., 1994). This hyperplasia 
occurred uniformly with 100% penetrance. We quantified epidermal thickness using Image J 
software. FVB/n wild type epidermis had an average epidermal thickness of 4.19 ± 0.73 x 103 
μM. The K14-HPV16 transgenic M5Cre- mice had a significant 4-fold increase of epidermal 
thickness compared to the FVB/n ctrls (average thickness of 13.75 ± 0.76 x 103 μM). In mast 
cell-deficient K14-HPV16+ RDTA M5Cre mice, epidermal thickness was on average 10.62 ± 
0.51 x 103 μM. Hyperplastic lesions of both groups advanced focally into dysplastic lesions. 
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In M5Cre+ and control mice, the keratinocytes from the basal and spinous cell layer acquired 
irregular shapes and nuclear morphology. 
 
In addition, hyper-para-keratosis and papillomatosis were frequently observed (Figure 3.10a). 
No significant differences were observed in the epidermal thickness in both groups of mice 
older than 6 months. The average epidermal thickness in the M5Cre negative group was 
22.10 ± 1.06 x 103 μM whereas M5Cre+ group had 19.59 ± 1.31 x 103 μM. This results 
suggests that mast cells do not alter HPV16 induced neoplastic growth of the epidermis which 
contradicts the previous findings that mast cells functionally compromises neoplastic 
progression in HPV16 mice (Coussens et al., 1999). 
3.2.2 Keratinocyte proliferation unaltered in the absence of mast cells 
Increased frequency of proliferating cells is one of the hallmarks of carcinogenesis and was 
also demonstrated in K14-HPV16 mice (Arbeit et al., 1994). We questioned whether mast 
cells influence the proliferative activity of keratinocytes in early and late neoplastic 
progression and analyzed skin of mast cell proficient and deficient K14-HPV16 mice for 
expression of the proliferation marker Ki67 that labels cycling cells. In control skin, few 
proliferating cells were detectable in the basal layer of the epidermis and hair follicles. A Ki-
67 proliferative index was calculated as number of Ki-67+ cells per total keratinocytes (see 
 
Figure 3.10: Loss of mast cells does not alter HPV16-induced epidermal pathology (A) H&E staining of 
FVB/n ear skin displayed single layer of keratinocytes. The transformed ear skin shows hyperplasia, 
dysplasia and papillomatosis in M5Cre- and M5Cre+ ear skin.  (B) Quantification of epidermal thickness 
determined in H&E staining by Image J software. At least 5 images per mouse was analyzed. n=3-5 
mice per group. P values - not significant, White bar – Negative littermate ctrl, black bar- K14HPV16+ 
RDTA+/+ Cre negative, red bar - K14HPV16+ RDTA+/+ M5Cre+ mice Scale bar 50 μM. 
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section 2.6.7). In normal epidermis, around 8% of keratinocytes were positive for Ki67-
staining. By 2 months, K14-HPV16 RDTA M5Cre negative ear sections revealed a 3-fold 
significant increase in cell proliferation in the entire epidermis compared to WT controls. 27.56 
± 3.8 % of epidermal keratinocytes expressed Ki-67 (n=3)). In the mast cell-deficient M5Cre+ 
group, a similar Ki-67 proliferative index (29.66 ± 3.8 %, n=3) found. In mast cell proficient 
and deficient K14-HPV16 transgenic mice, Ki67- positive cells were also detectable in 
suprabasal layers of the epidermis.  
 
In 6 months old mice, a significant increase in Ki-67 proliferative index were observed in both 
the K14-HPV16 transgenic groups. In mast cell-proficient K14-HPV16 transgenic group, 
32.79 ± 3.82 % of keratinocytes expressed Ki-67. The M5Cre+ ear skin sections also 
displayed a similar increase and feature a proliferative index of 41.35 ± 5.703 %, (n=4) 
reflecting, no significant differences in Ki-67 proliferative indices observed in mast cell 
proficient and deficient transgenic group. Altogether, these observations suggest that mast 
cells are not involved in the control of epithelial proliferation and in both the early and late 
stages of HPV16 neoplastic progression. 
 
Figure 3.11: Loss of mast cells does not affect HPV16 induced keratinocyte proliferation. Five-micron 
thick paraffin sections of K14HPV16+RDTA+/+M5Cre+, M5Cre- and FVB/n WT control mice were 
stained or Ki-67 immunohistochemistry (brown staining) and counterstained with methyl green. (A): In 6 
month-old wild type ear skin epidermis, only few cells in the basal layer and hair follicles express Ki-67 
antigen. Dysplastic epidermis from 6 month-old transgenic animals shows homogeneous Ki-67-positive 
cells throughout the epidermis in both M5Cre+ and Cre negative ctrls. Red dotted line – basement 
membrane. Scale bar 50 uM (B) Quantification of Ki-67+ cells determined as % Ki67+ cells. At least 5 
focal view per mouse was analyzed. n=3-4 mice per group. P values - not significant, White bar – 
Negative littermate ctrl, black bar- K14HPV16+ RDTA+/+, M5Cre-, red bar - K14HPV16+ RDTA+/+, 
M5Cre+ mice. 
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3.2.3 No significant changes in epidermal apoptosis in absence of mast cells 
In a mouse model of intestinal adenoma, mast cells were found to inhibit adenoma formation 
by stimulating apoptosis of adenoma cells without affecting their proliferating rate (Sinnamon 
et al., 2008). Ear skin of K14-HPV16+RDTA+/+M5Cre+ was characterized by similar 
keratinocyte proliferation indices. We next, investigated whether mast cells influence 
epidermal apoptosis in early and late neoplasia. To detect apoptosis, ear skin sections were 
assessed for TUNEL activity (Gavrieli, 1992), and TUNEL positive cells per mm epidermal 
length (dermal) were quantified. TUNEL positive cells were predominantly detected in the 
stratum granulosum in the early neoplastic stage. By 2 months, transformed ear sections of 
both groups had similar TUNEL activity. The M5Cre- group had 3.917 56 ± 0.28 TUNEL 
positive cells (n=3), whereas the M5Cre+ group had 3.897± 0.40 (n=3) positive cells. At the 
late neoplastic stage (6 months), the TUNEL activity in general increased consistent with the 
higher keratinocyte proliferation indices.  
At this stage, TUNEL positive cells were detectable mainly in a focal dysplastic lesions. No 
significant differences in the number of apoptotic cells were found between mast cell-
proficient vs mast cell-deficient K14-HPV16 transgenic skin at 2 or 6 months of age. 
Collectively, our data show that mast cells do not alter proliferation or apoptosis of 
transformed keratinocytes in K14-HPV16 transgenic mice. 
As shown below, absence of MCs does not impair tumour development or reduce epithelial 
proliferation. As MCs are one of the most frequent cell types in the inflammatory infiltrate, and 
since MCs are generally regarded as important orchestrators of tissue inflammation, we 
asked whether MC had any detectable impact on the cellular composition of the inflammatory 
stromal infiltrate or on the differentiation of infiltrating hematopoietic cells, in other words, 
whether they shape the immunological tumour micromilieu. 
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3.2.4 No detectable alterations of the Immune cell infiltrate in mast 
cell deficient K14-HPV16 mice 
To determine whether MCs influence composition of the inflammatory infiltration in the tumour 
stroma, K14HPV16+ RDTA+ M5Cre+ (MC deficient), M5Cre- (MC proficient) neoplastic and 
FVB/n control ear skin was subjected to enzymatic digestion (see section 2.5.1.2). Single cell 
suspensions were prepared and analyzed by flow cytometry.  
 
A specific gating strategy was adapted for analyzing immune cell infiltrate ear skin tissue 
(Figure 3.13). Standard forward and side scatter gatings are applied to separate immune cells 
from cellular debris and other cell artefacts. Height, area and width properties of forward and 
side scatter are applied to exclude doublets. To ensure accurate data interpretation, dead 
cells were excluded using propidium iodide (PI) staining. PI negative cells were gated as live 
cells depicted in the gating strategy. The CD45 surface marker was used to distinguish CD45- 
epithelial cells from CD45+ hematopoietic immune cells. Further analysis was performed on 
 
Figure 3.12: No changes in the rates of keratinocyte apoptosis in the absence of mast cells. (A) Five-
micron thick paraffin sections of K14HPV16+RDTA+/+M5Cre+, and their Cre negative control mice were 
used for TUNEL staining and counterstained with methyl green. (A) Dysplastic epidermis from 6 month-
old transgenic animals shows numerous TUNEL positive cells (brown staining marked by *) in both 
M5Cre+ animals and Cre negative ctrls. Red dotted line – basement membrane. Scale bar 50 uM (B) 
Quantification of TUNEL+ cells per mm tissue length. At least 5 mm epidermis was analyzed for each 
mouse. n=5 mice per group. P values not significant. White bar – Negative littermate ctrl, black bar- 
K14HPV16+ RDTA+/+, M5Cre-, red bar - K14HPV16+ RDTA+/+, M5Cre+ mice.  
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gated CD45+ cells for identification of various different subsets of immune cells with their 
respective surface markers. 
 
 
Figure 3.13: Gating strategy for the analysis of infiltrating immune cells in neoplastic tissue by flow 
cytometry. CD45+ immune cells were defined as propidium iodide (PI)-negative that predominantly 
expresses the cell surface markers CD45. Gated CD45+ cells were delineated for further immune 
cell subsets. Representative dot plots for Mast cells, CD11b, DCs, GR-1, and F4/80, and dot blots 
for lymphocyte subsets CD4-, CD8-, and CD19/B220-positive cells are shown. 
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To verify efficient mast cell depletion, mast cells were identified as cells double positive for 
the surface markers CD117 and FcepilonR1alpha. T lymphocytes were identified as CD3e+ 
CD4+ or CD3e+ CD8a+ t cells whereas B lymphocytes were identified by their expression of 
CD19. Natural killer t cells were identified as CD45+ NK1.1+ double positive cells.  
 
CD11b is a cell surface beta (2) integrin selectively expressed on granulocytes and 
macrophages. Thus CD11b+ve gated population are further subdivided into for granulocytes 
and macrophages with the surface markers GR1 and F4/80 respectively. Dendritic cells were 
identified as CD11b+ DCs and CD11b negative DCs. 
 
The ear skin cell suspensions contained keratinocytes, fibroblasts and other cell types in 
addition to hematopoietic cells (CD45+). The later accounted 18.860 ± 3.480% (Absolute cell 
count 191375 ± 101937 cells, n=4) of the total ear skin population in wild type mice. 
Transformed skin of MC proficient K14-HPV16 transgenic mice contained a 2-fold increase 
in CD45+ immune cells compared to the wild type controls. These mice accounted 37.88 ± 
3.954 % of CD45+ cells (Absolute cell count 379444 ± 60934 cells, n=9) of the total ear skin 
population). 
 
In comparison of MC proficient transgenic mice, Mast cell deficient K14HPV16 mice did not 
result in any significant difference in CD45+ population (46.45 ± 4.278% of CD45+ cells, 
339986 ± 71318 cells, n=7) of the total ear skin. 
 
Using Ckit and FcεR1alpha cell surface markers, mast cells are analyzed in wild type litter 
mate controls and transgenic mast cell proficient and deficient animals. WT mice contains 
9.303 ± 1.32 % of total CD45+ cells as mast cells with the absolute cell counts 3713 ± 2025, 
n=4. Mast cells in the MC-proficient K14HPV16 mice accounted for 5.053 ± 0.57 % of total 
CD45 cells (n=9) with the absolute cell number 6973 ± 1614, n=9. MC-deficient transgenic 
mice, also by flow cytometry are devoid of MCs as expected. Mast cells composition in this 
groups was significantly reduced, i.e, less than 0.2% of total CD45 cells (.026% ± 0.07, n=7) 
were mast cells with the negligible amount of absolute mast cell numbers 304.9 ± 97.75 cells, 
n=7. 
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Next, we profiled lymphocyte populations, i.e., CD4, CD8a T cells and CD19 B cells. CD4 T 
cells accounted 18.23 ± 2.35 % (Abs cell count 6639 ± 3395, n=4) of total CD45+ cells in wild 
type control mice. M5Cre- transformed ear skin contained 33.94 ± 2.05 % of total CD45 cells 
with absolute cell number 45807 ± 8976 cells, n=9.  Percentage of CD4T cells in MC-deficient 
transgenic mice reflected 38.12% ± 3.35 (32994 ± 6323, n=7 cells) of total CD45+ cells, 
however, MC-deficiency did not result in any difference on T cell infiltration. 
 
 
Cytotoxic T lymphocytes in the wild type mice had 4.193% ± 1.011 of total CD45+ cells with 
the absolute cell count 1373 ± 787.6, n=4. In the transformed neoplastic tissue, 8.55% ± 1.20 
of total CD45+ cells (14341 ± 3859, n=9) accounted for cytotoxic T lymphocytes whereas 
mast cell deficiency in the neoplastic tissue did not altered the cytotoxic T cell numbers. This 
group accounted for 8.123% ± 1.29 (9246 ± 2231, n=7) of CD8a T cells in the ear skin. In 
 
Figure 3.14: No significant changes in infiltrating immune cells in neoplastic tissue in the absence of 
mast cells. Ear skin of Negative Littermate ctrl, K14-HPV16 RDTA+ M5Cre+ abd M5Cre- controls were 
analyzed by FACS.  Gated on CD45+ cells and Absolute cell numbers of Mast cells, CD11b, DCs, GR-
1, and F4/80, and lymphocyte subsets CD4+, CD8+, and CD19+ B cells were quantified. n=4 (NLM), 9 
(MCpro) and 7 (MC def) group. White triangles – Negative littermate ctrl, black dots- K14HPV16+ 
RDTA+/+, M5Cre-, red dots - K14HPV16+ RDTA+/+, M5Cre+ mice. P value <0.0010. 
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addition, no significant changes in CD19 B cells population were observed in between the 
groups. Thus, mast cell deficiency does not alter the lymphocyte infiltration in neoplastic 
tissue. 
 
We also profiled granulocytes, neutrophils and DCs populations, i.e., F480, GR1 cells and 
CD11c dendritic cells in the ear skin of wild type, and transformed ear skin. In wilt type ear 
skin, CD11b+ cells accounted for 12.89 ± 3.23 % (Abs. cell count 4023 ± 1690, n=4) of total 
CD45+ population. M5Cre- transformed ear skin contained 6.61 ± 1.54 % of total CD45 cells 
as CD11b+ cells with the absolute cell number 11015 ± 2427 cells, n=9. MC-deficient 
transgenic mice reflected 12.03 % ± 7.47 (9719 ± 1887, n=7 cells) of total CD45+ cells. 
Further subgating these CD11b+ cells shows that more than 75% of CD11b+ cells are 
Granulocytes with the absolute cell count of 7623 ± 1650 cells, n=9, in MC proficient 
transformed skin. However, in absence of mast cells, there is no significant difference   
observed (Abs cell count 6257 ± 1234 cells, n=7) in this group.  
 
Likewise, no significant changes observed in the DCs in tumor microenvironment. Here, 
dendritic cells are characterized as the CD11b+ CD11c double positive cells.  Wild type litter 
mates accounted for 6.23 ± 1.29% of CD45+ cells as DCs. The transformed ear skin reflected 
5.91 ± 2.06% (14204 ± 3800 cells, n=9 )  of CD45+ whereas  again the absence of mast cells 
in the transformed skin reflected the similar range (2.89 ± 0.96%  (9071 ± 2199 cells, n=7) of 
DCs in tumor micro environment.  
 
Altogether, the data suggests that mast cells does not alter the immune cell infiltrate in tumour 
microenvironment. Therefore, mast cell does not or only slightly influence the inflammation in 
HPV16 induced neoplasia. 
 Loss of mast cells does not influence infiltrating immune 
cells at the transcriptome level 
Next, we investigated whether MCs have a detectable effect on the differentiation of 
inflammatory hematopoietic cells of the tumour stroma. We addressed this question by 
comparing the transcriptomes of non-MC hematopoietic (CD45+) cells from tumour tissue of 
MC-proficient versus MC-deficient mice. To this end, live (PI-negative) CD45+ cells that were 
negative for the MC marker Kit were sorted by FACS from ear tissue cell suspensions (see 
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sections 2.5.1.2) of two-months-old and six months-old K14-HPV16 M5Cre R-DTA and their 
Cre-negative littermate controls, RNA was extracted and the transcriptome was sequenced 
by Illumina-based massive parallel sequencing. 
 
This design was prone to a systematic artefact since the genetic MC depletion in M5Cre R-
DTA mice is inevitably more complete than the flow cytometric depletion of the MCs in the 
MC-proficient samples by gating on non-MCs.  
 
Figure 3.15: (A) Gating strategy for flow cytometric purification (‘sorting’) of hematopoietic non-MCs and 
total hematopoietic cells (including MCs) from tumour tissue of MC-proficient K14-HPV16 mice that were 
two or six months of age. B) ‘MA plot’ showing significantly deregulated genes in the two months 
comparison in red and those of the six months comparison in blue. Significantly deregulated genes up-
or downregulated more than two-fold are listed in table 3.1. 
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Table 3.1: List of genes identifies as specific for the tumour MC population by comparison of MC-depleted 
CD45+ cells with total CD45+ cells from MC-proficient K14-HPV16 mice at the two months and the six-
month time points. These genes were excluded from the transcriptome comparison of non-MC CD45+ cells 
from MC-proficient and MC-deficient tumour tissue. 
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The few residual MCs miss-sorted into the non-MC CD45+ samples from the MC-proficient 
tumour tissue would always be visible as a MC signature in the transcriptome comparison, 
which was not of interest in this experiment. Therefore, we aimed to exclude MC-specific 
genes from our transcriptome comparison and first established a list of genes specifically 
expressed in the tumour MC population. To this end, two samples of CD45+ cells including 
MCs were sorted from ear skin suspensions of MC-proficient tumour tissue of two months-
old mice and two samples from six months-old mice (Figure 3.15a). The transcriptomes of 
these four samples were compared to those of non-MC CD45+ cells from MC-proficient 
tissue. This comparison identified genes that were specific for the tumour MC population (a 
MC transcriptional signature, Figure 3.15b); All differentially expressed genes in this 
comparison were excluded from the subsequent transcriptome comparison between non-MC 
CD45+ cells from MC-proficient versus MC-deficient tumour tissue.  
 
 
CD45+ non-MCs were sorted flow cytometrically from MC-proficient and MC-deficient K14-
HPV16 skin from animals aged two months (MC-proficient mice n=3, MC-deficient n=4) or six 
months (MC-proficient mice n=5, MC-deficient n=5). The gating strategy is shown in Figure 
3.16. Total RNA was isolated from the sorted cells. Subsequently mRNA libraries were 
prepared and subjected to deep sequencing on an Illumina ® HighSeq platform yielding 
between 30 and 60 million reads per sample. 30% of these were mapped to exonic regions 
on mus musculus genome reference assembly “mm10” using the genomic short-read 
nucleotide alignment program (Wu and Nacu, 2010). Differential expression of genes 
between the groups was calculated using the DEseq2 (v1.80) package in Bioconductor (Love 
et al., 2014). The result of the transcriptome comparison of CD45+ cells from MC-proficient  
 
Figure 3.16: Gating strategy for sorting of non-MC CD45+ hematopoietic cells from ear skin 
suspensions for RNA seq analysis and representative examples of a post-sort reanalysis, 
demonstrating the high efficiency of MC depletion. 
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versus MC-deficient transformed K14-HPV16 skin is shown in Figure 3.17. At the two months’ 
time point, 23 genes were found deregulated more than two-fold in CD45+ immune cells from 
MC-deficient tissue compared to CD45+ cells from MC-proficient skin (after subtraction of 
MC-specific genes). Four genes were up-regulated, 19 were down-regulated. These 
deregulated genes were functionally completely heterogeneous, i.e. none of them was part 
of the same cellular pathway or process as determined by ‘pathway analysis’ using the 
Panther online tool (www.pantherdb.org). 
 
Figure 3.17: Transcriptome comparison of CD45+ cells (non-MCs) from MC-proficient versus MC-
deficient K14-HPV16 skin from two months-old mice (A) or six months-old mice (B). MC-specific genes 
were subtracted and are not included. 
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Table 3.2: List of genes significantly deregulated in CD45+ cells of MC-deficient compared to MC-proficient 
K14-HPV16 skin tissue from two months-old mice. Genes with more than 2-fold change of transcript levels 
are shown. The MC-specific genes (see table 3.1) and genes known to be expressed only in non-
hematopoietic cells (e.g. keratin genes) are not shown. 
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Table 3.3: List of genes significantly deregulated in CD45+ cells of MC-deficient compared to MC-proficient 
K14-HPV16 skin tissue from six months-old mice. Genes with more than 2-fold change of transcript levels 
are shown. The MC-specific genes (see table 3.1) and genes known to be expressed only in non-
hematopoietic cells (e.g. keratin genes) are not shown. 
 
 
At the six months’ time point, 9 genes were found deregulated more than two-fold in CD45+ 
immune cells from MC-deficient tissue compared to CD45+ cells from MC-proficient skin 
(after subtraction of MC-specific genes), all of which were up-regulated. Again, all upregulated 
genes were functionally heterogeneous, and none of them was part of the same cellular 
pathway or process as determined by ‘pathway analysis’ using the Panther online tool 
(www.pantherdb.org).  
In summary, the absence of MCs in transformed K14-HPV16 skin did not cause any relevant, 
systematic changes in the transcriptomes of other hematopoietic cells in the tissue, which 
constitute the inflammatory infiltrate. The few genes that the transcriptome analysis identified 
as significantly deregulated in the samples from MC-deficient compared to control tissue were 
all only moderately up- or downregulated and were functionally heterogeneous. Therefore, 
with high likelihood, deregulation of these genes does not reflect the absence of a MC 
function, but represents experimental noise. We conclude that MCs don’t significantly 
influence the composition of the inflammatory infiltrate of HPV16-transformed skin and have 
no impact on the differentiation of other hematopoietic cells of the tumour micromilieu. 
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 Squamous cell carcinoma (SCC) incidence 
3.4.1 Development of SCC in the absence of MCs 
As described in previous chapters (Section 3.2 & 3.3), early stages of tumour development, 
i.e. HPV-induced hyperplasia and dysplasia, are not altered by the loss of MCs. An important 
question was, whether the progression from the dysplastic stage to invasive carcinoma would 
occur in the absence of MCs. We monitored a cohort of ageing mice to assess SCC incidence. 
SSC arose also in MC-deficient mice. 
  
3.4.2 MC ablation in SCC tissue 
SCC tissue in K14-HPV16 mice harbours high numbers of MCs which likely are actively 
recruited into the tumour tissue and are also stimulated to proliferate in the tumour. Therefore, 
the question whether MC depletion would be effective in SSC tissue of old K14HPV16+ 
M5Cre RDTA+ mice was important. MC numbers in SSC tissue were determined by 
histological analysis of Giemsa-stained tissue sections (Figure 3.18). MCs in SCC tissue were 
significantly ablated (the average depletion efficiency was 93.54% when compared to 
controls) in K14-HPV16 mice upon de-repression of suicidal diphtheria toxin expression in 
mature MCs in K14HPV16+ RDTA+M5Cre+ mice. MCs were quantified as the total number 
of MCs per field of vision (FOV) at the tumour periphery. The average number of MCs in 
SCCs was approximately 31 cells per FOV in K14HPV16+ RDTA+M5Cre- control SCC 
sections, whereas the average number of MCs in K14HPV16+ RDTA+M5Cre positive 
sections was only two cells per FOV. This indicated that in M5Cre + tissue sections, MCs 
were reduced by >15-fold (6.4% of total MCs in SCCs compared to the Cre- controls).  
3.4.3 Incidence of SCC in MC-deficient and MC-proficient mice 
To evaluate whether the absence of MCs influences SCC incidence, a cohort of ageing mice 
was routinely monitored. The MC-proficient group consisted of 28 transgenic mice; the MC-
deficient group contained 19 transgenic mice. The latter exhibited a similar macroscopic 
phenotype as was published in the original publication of the K14-HPV16 mouse line (Arbeit 
et al., 1994) with papillomatosis of the ear skin, snout and chest skin (Figure 3.18). This result 
demonstrates that MCs are not required for transformation of dysplastic skin to invasive SSC.  
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With 100% penetrance, both groups developed hyperplastic skin that was first detectable at 
the time of weaning. By four to six months, all animals of both groups featured thickened, 
inflamed ear skin with prominent papillomatosis and hyperkeratosis. The incidence of 
histologically detected dysplasia at four to six months of age was not different between the 
groups. By the age of 13 months, 38% of the MC-proficient mice had developed SSC, 
compared to 52% in the MC-deficient group (Figure 3.20b). The mean age at first 
 
Figure 3.18. Phenotype of mc proficient and deficient HPV16 mouse. 10 months old ear pinna of a) 
wild-type FVB/N mouse compared with (b) K14-HPV16 mast cell proficient and (c) K14-HPV16 mast 
cell deficient mouse. Transgenic mice (b and c) exhibit growth retardation and severe thickening and 
lesions on the ears and snout, papilloma’s in the ear, snout and cornfied crust in the ear skin.  
 
 
Figure 3.19. Ablation of cutaneous mast cells in squamous cell carcinoma tissue (SCC).                
(a) Paraffin sections of SCC tissue from MC proficient and deficient mice were stained with Giemsa to 
detect mast cells (purple color). Scale bar represents 100μm. b) Total number of mast cells was 
quantified as mast cells/field of vision (FOV). Black bar represents mc proficient tumor tissue (n=7), 
red bar represents mc deficient tumor tissue (n=7). Error bar represents mean ± SD. t-test was used 
to calculate significance. P value ****< 0.0001. 
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manifestation of SCC (>5 mm diameter) was 363 days in MC-proficient mice, whereas MC-
deficient mice developed SCC at a mean age of 348 days (Figure 3.20a).  
 
3.4.4 Histopathological classification of SCC tissue 
Histopathological examination by an expert dermato histopathologist, Dr. Iliana Tantcheva-
Poor, Cologne, confirmed the macroscopic diagnosis of SSC in all cases. In most cases, 
invasive SSC was found, while an in situ carcinoma was diagnosed in a smaller number of 
 
Phenotype 
(age in month) 
MC proficient mice 
N4, n=28 
MC deficient mice 
N4, n=19 
Hyperplasia (2) 100% 100% 
SCC (8-12) 35.7% (10/28) 52.63% (10/19) 
Figure 3.150. (a) Kaplan Meir analysis for SCC free survival. P=0.5905, Log Rank test. (b) Percentage 
of SCC occurrence in mast cell proficient and deficient mice. Mast cell proficient mice n=28, mast cell 
deficient mice n=19. Histopathological score of MC proficient and deficient tumor tissue. Hyperplasia 
of ear epidermis in was quantified as % of all analyzed sections.  
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cases. Few mice had developed a second SSC by the time they were sacrificed. In situ SCC 
of the skin was classified based on the scheme described by Joshua A. Gross et al. (Gross 
and Perniciaro, 2015), in which the multi-centric SCC in situ (SCCIS) tissues were classified 
into six main histopathological subtypes (Figure 3.21 & Table 3-4). 4 of the types of multi-
centric insitu carcinoma are shown below (Figure 3.21) 
 
 
 
Figure 3.21. H&E stainings of SCC tissue sections. Tumor grading classified based on the 
histopathological type and its degree of keratinocyte differentiation. a) Verrucoid verruca b) HPV horn c) 
Kerato acanthoma d) Bowenoid type. Insitu carcinoma classification based on histopathological subtype 
as previously described. Images are not to the scale. 
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Figure 3.22. H&E staining’s of invasive squamous cell carcinoma tissue. Classification based on the on 
histopathological subtype and degree of on the degree of keratinocyte differentiation. A) Scanning 
magnification shows the spindle cells SCC. b) Inflammatory type SCC, c) Kerato acanthoma like SCC 
d) Well differentiated SCC, where keratinization is predominant e) Poorly differentiated SCC where, 
most of the tumor as focused here lacks keratinization, f)  Moderately differentiated carcinoma where 
only parts of the tumor shows keratinization. Images are not to the scale. 
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Table 3.4: Histological grading of MC proficient and deficient cancer tissue 
Parameters MC proficient cancer tissue 
 
MC deficient cancer tissue 
SCC Incidence 
 
 
  
Occurrence (mean days) 363 days 348 days 
   
Cancerous Tissue   
Total no of  cancerous tissue 12 14 
Localization   
Ear 6 (50%) 8 (57%) 
Neck - 1 (7%) 
Chest 1 (8%) 4 (28%) 
Back 5 (45%) - 
Abdomen - 2 (14%) 
Fore leg - 1 (7%) 
   
SCC classification   
In-situ   
Actinic   
Bowenoid 2 4 
Verrucoid   
Acanthotic   
Seborrheic keratosis - like 2  
Dyskeratotic   
   
Invasive   
Well differentiated 6 (50%) 4 (28%) 
Moderately differentiated 1 (8%) 2 (14%) 
Poorly differentiated 1 (8%) 4 (28%) 
Keratoacanthoma-like - 1 (7%) 
Acantholytic - 1 (7%) 
Spindle cell / Sarcomatoid 2 (16%) 2 (14%) 
   
Other types   
Sebaceous adenoma 2 2 (14%) 
Cyst 0 1(7%) 
   
   
 
Invasive SSC was histologically classified according to Broders et al (Broders et al; 1951) 
based on the degree of keratinocyte differentiation. Well-differentiated tumours resemble 
normal squamous epithelium with keratinisation, whereas moderately-differentiated tumours 
exhibit higher numbers of pleomorphic nuclei, higher mitotic activity, including atypical 
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mitoses and reduced keratinisation. In poorly-differentiated carcinoma, immature cells with 
minimal or no keratinisation feature numerous typical and atypical mitoses. In addition, 
keratoacanothoma-like invasive SCC and inflammatory type SCC are classified under 
Invasive SCC (Figure 3.22 & Table 3.4) Table 3.4 lists the tumour grades and histological 
subtypes observed in our MC-proficient and MC-deficient K14-HPV16 mice. No significant 
difference in tumor grading and its characterization observed between the two groups. 
In conclusion, Mast cell deficiency in K14-HPV16 transgenic mice does not alter SCC 
incidence, tumour grading or SSC subtype. Collectively, our data demonstrate that MCs are 
of no relevance in HPV16-induced cancer initiation and progression in K14-HPV16 mice.  
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 Discussion  
Mast cells (MCs) are found in most tissues but are most frequent in the skin and at mucosal 
surfaces of the body. These long-lived immune cells accumulate in high numbers in the 
stroma and along the invasion front of various human cancers. Mast cells belong to the innate 
immune system and express a broad array of pattern recognition receptors. Upon activation, 
they can release, depending on the quality of the stimulus, different spectra of important pro-
inflammatory, immunostimulatory, but also anti-inflammatory and immunoregulatory as well 
as angiogenic mediators. Thus, their functions in cancer biology might be tumour-promoting 
or tumour-suppressive. Earlier studies have addressed the role of MCs in various neoplasms 
using Kit-mutant MC-deficient mice. Reduced tumour growth was observed in these mice, 
suggesting that MCs are important tumour promoters. However, due to the complex 
alterations of the entire immune system that characterize Kit-mutant mice in addition to their 
MC deficiency, these results are difficult to interpret. Many phenotypes of Kit-mutant mouse 
strains did not reproduce in novel Kit-independent mouse models of MC deficiency. 
Therefore, the contribution of MCs to cancerogenesis is presently unclear. We crossed the 
K14-HPV16 transgenic mouse model of skin cancer onto the R-DTA M5-Cre mouse line, 
which is MC-deficient but features an otherwise normal immune system. Our results 
unambiguously demonstrate that MCs are dispensable for the cancerogenesis and 
progression of HPV16-induced neoplasia and development of SCC.  
 RDTAxM5Cre – A novel Kit-independent mouse model of 
MC-deficiency free from haematopoietic abnormalities 
Over the past decades, in vivo functions of MCs were investigated using mice carrying 
mutations in the Kit gene. Both, KitW/W-v and KitW-sh/W-sh mice are profoundly MC-deficient in 
all tissues. Adult Kit mutant mice exhibit less than 1% of the wild type (WT) MCs in their skin 
(Kitamura et al., 1978). However, Kit is expressed, in addition to MCs, in hematopoietic 
precursors of all lineages. Therefore, reduced Kit signaling in KitW/W-v and KitW-sh/W-sh mice 
results in complex abnormalities of the immune system. KitW/W-v mice develop neutropenia 
and macrocytic anaemia, lack intestinal γδ cells, and also develop spontaneous dermatitis, 
gastric ulcers and papillomas of the stomach (Grimbaldeston etal; 2005). In contrast, KitW-
sh/W-sh mice are characterised by an enlarged spleen, increased numbers of splenic myeloid 
cells and megakaryocytes, and have neutrophilia and thrombocytosis (Nigrovic et al., 2008b) 
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Importantly, these lines behave differently in inflammatory conditions, and particularly in 
cancer models (Coussens et al., 1999; Sinnamon et al., 2008). Thus, a kit-independent MC 
deficiency mouse model is essential to validate the in vivo functions of mast cells in various 
pathologies. Consequently, an M5Cre mouse strain was generated which allows for either 
inducible or for constitutive depletion of MCs by Cre-loxP-mediated recombination technology 
(Scholten et al 2008, Dudeck et al 2012). The tumor model used in the present study (K14-
HPV16 mice), in which cancer development occurs at old age, long-lasting constitutive 
depletion of MCs was required. We therefore relied on the RDTA x M5Cre mouse model.  In 
M5Cre animals, specific expression of a Cre-transgene was achieved in connective tissue 
MCs by replacing the first exon of the Mcpt5 gene using BAC-recombineering and 
subsequent injection of the modified BAC into the pronucleus of fertilized eggs (Scholten et 
al., 2008). Activation of the Mcpt5 promoter is highly specific for connective tissue MCs and 
was successfully used to inactivate genes selectively in MCs (Scholten et al., 2008b). 
ROSA26 flox-STOP-flox diphtheria toxin A knock in (R-DTA) mice allow controlled expression 
of diphtheria toxin A upon Cre-mediated deletion of the loxP flanked stop cassette positioned 
upstream of the DTA-cDNA. By expression of DTA, the cells kill themselves. The R-DTA 
based system has been successfully applied for constitutive depletion of various other 
immune cell populations, including T cells (Vohringer et al., 2008), dendritic cells (Ohnmacht 
et al., 2009) and eosinophils (Doyle et al., 2013). Intercrossing of the M5Cre and R-DTA 
mouse strains resulted in selective and efficient depletion of mature connective tissue type 
MCs in M5Cre R-DTA animals. In adult RDTAKi/KiM5Cre+ mice, at least 96% of the MCs were 
depleted in the peritoneal cavity, and a similar depletion efficiency (97%) was observed in ear 
skin without affecting other haematopoietic subsets (Figure 3.1–3.2) as determined by flow 
cytometry. Rare misgating events will likely result in overestimation of the residual MC 
number. Accordingly, histological analysis of skin tissue sections from various anatomical 
sites, including the ear, back skin, tail base and abdomen, showed almost complete absence 
of MCs (Figure 3.3) Thus, the extent of MC depletion efficiency was comparable to that 
observed in adult KitW/WV mice, in which <1% of skin MCs were detected ((Kitamura et al., 
1978)). As expected, no alterations were observed in other haematopoietic cell subsets in the 
skin upon Cre mediated recombination (Figure 3.2). Similarly, haematopoietic cell 
populations in spleen, blood and bone marrow were not altered RDTAKi/KiM5Cre+ mice (data 
not shown). This near complete MC deficiency was manifest already at young age in contrast 
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to MC numbers in KitW-sh/W-sh mice, which are born with almost normal MC numbers but 
gradually loose them until the age of about three months (Grimbaldeston et al; 2005).  
In addition to MC deficiency, Kit mutant mice are anaemic and neutropenic. This was a major 
limitation in the interpretation of the exclusive in vivo MC functions in inflammatory conditions. 
Nigrovic et al. showed that KitW-sh/W-sh mice exhibit neutrophilia and thrombocytosis, while 
KitW/W-v mice are mildly neutropenic (Nigrovic et al., 2008b). Resistance of KitW/W-v mice to 
antibody-mediated arthritis is likely due to the low levels of circulating neutrophils (Zhou et 
al., 2007). In contrast to the kit mutants, the data of the present study show that the RDTAki/ki 
M5Cre+ mice have normal levels of all major blood cell subsets including platelets and 
basophils. In this respect, RDTAkiki M5Cre mice have an advantage over Cpa3Cre/+ and 
Cpa3Cre-Mclfl/fl mice, two additional Kit independent MC deficiency mouse models. In these 
models, a reduction in blood basophils numbers was observed ((Feyerabend et al., 2005) 
(Lilla et al., 2011a)). RDTAki/ki M5Cre mice also displayed normal numbers of erythrocytes, 
normal haematocrit and haemoglobin levels.  
Moreover, unlike kit mutant mice, which are characterized by a high incidence of spontaneous 
idiopathic dermatitis and stomach lesions at an old age (Grimbaldeston et al., 2005a)), no 
macroscopic spontaneous phenotypes were observed in RDTAki/ki M5Cre animals.  
In summary, in the RDTAxM5Cre mouse model, MCs are depleted with high efficiency and 
specificity compared to the traditional kit mutant mouse strains. They feature a normal 
haematopoietic system and fertility and represent an ideal mouse model for studying MC 
biology in vivo. 
 HPV-induced neoplasia accumulates high numbers of 
MCs.  
Like human HPV-induced skin lesions, including benign warts and squamous cell carcinoma 
(SSC), the dermal tumor stroma of transformed skin in K14-HPV16 transgenic mice contains 
high numbers of MCs. MC accumulation underneath the basement membrane is conspicuous 
already at the earliest epidermal changes detectable. The first increase in the number of 
dermal MCs coincides with the angiogenic switch, i.e. the sudden increase in blood vessel 
diameter and density that occurs early in epithelial transformation. MC number steadily 
increases thereafter in parallel to disease progression. A three-fold increase in MC numbers 
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compared to the WT at the early hyperplastic stage in MC-proficient K14-HPV16 mice was 
observed, which increased to an eight-fold increase in MC numbers in the dysplastic stage. 
At later stages, MCs dominate the inflammatory infiltrate of the tumour stroma along with 
macrophages. The MC density correlated with epidermal thickness. Thus, the striking MC 
accumulation was highly suggestive of an important function of MCs in the biology of HPV-
induced tumours. In contrast, in other tumour mouse models that were employed to address 
MC functions in tumour biology, such as the pancreatic and intestinal adenoma models 
(Gounaris et al., 2007; Schönhuber et al., 2014), MC numbers are less dramatically increased 
and either reduce or remain constant throughout disease progression. In Pdx1-Flp;FSF-
KrasG12D/+ a pancreatic ductal carcinoma mouse model, the mean number of mast cells 0.2 
cells/FOV (Schonhuber et al., 2007). Similarly, TS4-CreERT2 × Ctnnbllox(ex3) an intestinal 
adenoma infiltrated ≈20 mast cells / FOV compared to 1.3 ± 1.6 mast cells in the control tissue 
(Gounaris et al., 2007).  
Coussens et al. showed that the MC infiltration observed in K14-HPV16 transgenic mice was 
not due to infections or infiltrating lymphocytes in the tumour microenvironment ((Coussens 
et al., 1999)). K14-HPV16 transgenic mice treated with antibiotics or bred into Rag1/null 
background (lacking mature lymphocytes), had a similar MC infiltration rate in dysplastic 
tissue, suggesting that the recruitment signal arises in the neoplasia itself. Most likely, the 
HPV-transformed keratinocytes secrete a MC recruiting factor. Stem cell factor (SCF), the 
key MC growth factor known to regulate MC survival, proliferation and homeostasis (Galli et 
al., 1994), is released by normal keratinocytes. SCF is expressed as a transmembrane 
protein on keratinocytes in the skin that can be cleaved by MC chymases to its soluble form 
(Longley et al, 1997). In the Kit mutant mice, in which the mutation in the SCF, the growth 
factor itself results in profound MC deficiency. Expression of SCF and its receptor are 
elevated in SCC tissue, with nearly 30% of tumour cells expressing SCF ((Pietsch et al., 
1998)). Therefore, SCF represents a candidate cytokine that might be responsible for the 
recruitment of MC to the tumor. Investigating MC density in K14-HPV16 mice with 
keratinocyte-specific SCF knock-out (KO) could be a way to address this hypothesis. 
71 
 
 Establishment of constitutive MC deficiency in K14-
HPV16 mice 
K14-HPV16 transgenic mice develop SSC only on the permissive genetic background FVB/n. 
Our two mouse lines M5Cre and R-DTAki/ki were generated on the C57JBL6 background and 
were therefore were backcrossed onto the FVB/n background for at least four generations. 
Subsequently the mouse strains were intercrossed with K14-HPV16 mice to yield the final 
MC-deficient SSC model (K14-HPV16+R-DTA+M5-Cre). These mice were viable and 
reproduced in expected Mendelian ratios on the FVB/n genetic background. Reproduction of 
the K14HPV16 SSC phenotype in the K14HPV16+RDTA+M5Cre animals shows that 
sufficient backcrossing was performed.  
While we had shown highly efficient MC depletion in healthy skin of M5Cre R-DTAki/ki animals, 
the question of how the potent MC-recruiting stimuli that are active in transformed K14-HPV16 
would impact on MC numbers still was an important open question. We were pleased to find 
that also in K14HPV16+RDTA+M5Cre+ mice, a near 100% depletion of MCs was achieved, 
with a high efficiency and selectivity that persisted until the SCC stage (Figure 3.7). The 
depletion efficiency in this mouse model was consistent throughout the different stages of 
neoplastic progression (Figure 3.7b).  
In K14-HPV16 mice heterozygous for the R-DTA allele (R-DTAki/wt), we observed few 
accumulations of MCs in the otherwise completely MC-deficient skin. These ‘MC colonies’ 
most likely represent a clonal outgrowth from a single MC, which escaped the Cre-induced 
suicide mechanism (Figure 3.8). Clonal expansion is driven by the proliferation stimuli from 
the neoplastic epidermis. This resistance of very few cells could be caused, for example, by 
rare point mutations in the Cre- or the DTA-cassettes. Similar observations were reported 
also for other mouse models that are based on R-DTA-mediated constitutive cell ablation. 
Ohnmacht et al. showed that nearly 10% of dendritic cells were retained in CD11c-Cre mice 
heterozygous for the R-DTA allele. Voehringer et al. showed that some T cells, which were 
resistant to Cre-activity, escaped depletion and were capable of proliferating despite 
expressing Cre-recombinase (Xing et al., 2011). Moreover, approximately 10% of eosinophils 
were retained in a cross of an eosinophil-specific Cre mouse line to the R-DTA line. Rarely, 
single MC colonies were also identified in K14-HPV16+R-DTAki/ki M5Cre+ animals 
homozygous for the R-DTA allele (Figure 3.9). However, the rare reappearance of these small 
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isolated MC colonies at late stages of tumour progression is unlikely to have any significant 
impact on the tumour biology.  
In conclusion, the K14-HPV16 line on the background of our new, Kit independent M5Cre R-
DTA MC-deficiency model represents a valuable tool to clarify the role of MCs in 
cancerogenesis and tumour growth. 
 Progression of HPV16-induced neoplasia is not impaired 
by the absence of MCs. 
We analysed the effects of MCs on the HPV-induced skin tumour by comparing MC-deficient 
M5Cre+, K14HPV16+ R-DTAki/ki mice and their MC-proficient M5Cre-negative R-DTAki/ki 
K14HPV16+ littermates. Despite near complete absence of MCs in the M5Cre+ mice, no 
differences between the two groups in the epidermal phenotype were found at an early (2 
months) and a late (6 months) time point. Epidermal thickness and numbers of epidermal 
cells positive for the proliferation marker Ki67 were similar to that of MC-proficient mice. 
These findings unambiguously demonstrate that MCs are dispensable for HPV-induced 
epidermal hyperplasia. Moreover, the progression from hyperplasia to the dysplastic stage, 
with abnormal nuclei appearing in suprabasal epithelial strata was not different between MC-
proficient versus MC-deficient mice. Thus, the keratinocyte hyper proliferation and transition 
to dysplasia in this mouse tumour model is completely independent of MCs. 
The fact that MCs accumulate in high numbers in HPV-transformed skin and are capable of 
releasing mediators that could promote tumour growth, like e.g. VEGF, stimulated the concept 
that MCs are important tumour promoting cells. Coussens et al. had performed a study on 
the contribution of MCs to HPV-induced tumour progression by crossing the K14-HPV16 
model onto the KitW/W-v strain (Coussens et al., 1999). The authors of this study, however, met 
the problem that the KitW/W-v mutations are lethal on the FVB/n genetic background. They bred 
extensively, but obtained only a single KitW/W-v K14-HPV16 FVB/n offspring, instead of 89 that 
were expected according to Mendelian laws. The single surviving MC-deficient mouse 
unfortunately died at the age of two months and was analysed for signs of epithelial 
hyperplasia and angiogenic switch. Keratinocyte proliferation and tumor-neoangiogenesis 
were reduced compared to MC-proficient control mice. These results obtained in one single 
animal were prominently published in 1999 and has received enormous attention since then. 
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The study is frequently cited to underpin tumour-promoting functions of MCs, despite the fact 
that the low number of mice (n=1) that were used to generate results precludes interpretation 
of the results. The single surviving offspring likely carried an additional genetic abnormality 
that partly balanced the lethal effect of the hypomorphic Kit expression on the FVB/n 
background but could also have a major effect on the epidermal tumour phenotype. 
MCs were shown to directly mediate tumour cell apoptosis via the secretion of the soluble 
factor TNF. Moreover, MC-specific enzymes, such as chymase and granzyme B, were 
reported to enhance apoptosis of epithelial cells (Sinnamon et al., 2008). However, despite 
the high MC density in K14HPV16+RDTAki/ki M5Cre+ mice, only few apoptotic cells were 
observed in the dysplastic epidermis and epithelial apoptosis rates did not differ between MC-
proficient and MC-deficient dysplastic tissues (Figure 3.12). Thus, it can be concluded that 
MCs influence neither proliferation nor apoptosis in HPV-transformed mouse epidermis.  
 MCs have no detectable impact on the immunological 
tumour microenvironment 
Most human cancer tissues are generally infiltrated by inflammatory cells, which can reflect 
the immune system’s attempt to kill the tumour cells. Frequently, the tumour cells corrupt the 
local immune response and program inflammatory cells to promote, rather than fight, the 
tumour. In the case of the K14-HPV16 tumour model, de Visser et al. showed that B cells are 
necessary to maintain chronic, protumourigenic inflammation in K14-HPV16 mice. Genetic 
deletion in RAG-/-k14-HPV16 mice resulted in a failure to initiate chronic inflammation during 
pre-malignancy and in diminished pre-malignant progression as well as a reduced carcinoma 
incidence. The transfer of B lymphocytes or serum isolated from K14-HPV16 mice into RAG-
/-HPV16 mice restored chronic inflammation (de Visser et al; 2005). Andreu et al. 
demonstrated that this proinflammatory and tumour promoting effect of adaptive immunity in 
this tumour model was dependent on antibodies and activating Fc receptors. Collectively, 
immune cells infiltrating into the stroma are necessary for disease progression in K14-HPV16 
mice (Andreu et al., 2010).  
MCs are regarded as orchestrators of tissue inflammation. Complex effects of MCs on innate 
and adaptive immunity have been reported, largely based on experiments in Kit-mutant mice 
(Galli et al., 2008a; Marshall, 2004). Since MCs are one of the most frequent cell types in 
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K14-HPV16-transformed skin, we asked whether, these cells, while not required for tumour 
growth, exert detectable effects on the tumour micromilieu. We therefore compared the 
cellular composition of the hematopoietic (CD45+) inflammatory cells of transformed skin in 
MC-proficient and MC-deficient K14-HPV16 mice by flow cytometry. No significant difference 
in the composition of the immune cell infiltrate could be detected. We next asked, whether 
loss of the MC population induces a change in transcriptional profiles of tumour-infiltrating 
leukocytes that might reflect an effect of MCs on the differentiation state of leukocytes in the 
tumour stroma. Therefore, we sequenced the transcriptomes of CD45+ non-MCs from MC-
proficient and MC-deficient transformed skin. However, only few significantly deregulated 
genes were identified that did not cluster into any common pathway and, most likely reflect 
only experimental noise. Thus, the absence of MCs was not reflected in any change of the 
composition of inflammatory infiltrate nor did the lack of MCs alter differentiation of the stromal 
leukocytes. 
Our findings are similar to those observed in Pdx1-Flp; FSFKrasG12D/+ a pancreatic ductal 
carcinoma (PDAC) mouse model that are based on Cpa-3/Cre mediated MC deficiency. 
Schonbauer et al. showed that, the mRNA expression analysis of genes relevant to PDAC in 
mast cell proficient and deficient tumor tissue revealed no significant (P < 0.05) differences 
due to mast cell ablation concluding that mast cells do not influence PDAC development 
(Schönhuber et al., 2014).  
In summary, the absence of MCs had no impact on epidermal proliferation, apoptosis rate, 
composition and differentiation of the immune cells infiltrating the tumor stroma. Our findings 
are in sharp contrast to earlier studies in Kit-mutant mice describing important tumor-
promoting functions of MCs ((Coussens et al., 1999; Gounaris et al., 2007; Soucek et al., 
2007),  
 Absence of MCs does not reduce incidence of SCC in 
K14HPV16 mice 
K14-HPV16 mice develop SSC with an incidence of about 50% at the age of 10-12 months. 
As described above, early stages of tumor development, i.e. hyperplasia and dysplasia, are 
not altered by the loss of MCs. An important question was, whether the progression from the 
dysplastic stage to invasive carcinoma would occur in the absence of MCs. We showed that 
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also at these late stages MC depletion in the MC recruiting environment of the tumor tissue, 
MC were virtually absent in M5Cre R-DTA mice. SSC were detected at a similar incidence 
and at a similar mean age of the animals in MC-deficient versus MC-proficient littermate 
controls. We also noted no difference in SSC progression and histological grading between 
the two groups. This result clearly demonstrated that MCs have no essential role in SSC 
biology. 
In a similar experimental setup, mice lacking matrix metallo proteinase 9 (MMP9) displayed 
a reduced incidence of malignant conversion (Coussens et al., 2000). Only 27% of 
HPV16/MMP-9 –/– mice developed invasive SSC, in contrast to an incidence of 
approximately 50% in MMP-9-proficient/HPV16 mice. It has been previously shown that 
MMP9 in neoplastic tissue is expressed by MCs and by neutrophils and macrophages. In 
contrast, in K14HPV16 R-DTA M5Cre mice where MCs are selectively depleted without 
affecting neutrophils and macrophages, incidence of malignant transformation was not 
reduced (Figure 3.20 & Table 3.4). Our data suggest that MMP9 from myeloid cells rather 
than MMP9 from MCs is effective in promoting tumor progression. 
In conclusion, using K14HPV16 M5Cre RDTA mice, this study demonstrates that MCs do not 
promote HPV-induced carcinogenesis  
 Perspectives 
Despite massive recruitment of MCs into tumour tissue of HPV-induced neoplasia in mouse 
and man, these cells have no detectable function in the biology of the tumour as our 
experiments unambiguously demonstrate. MCs are present in high numbers, but are merely 
innocent bystanders and neither promote nor impair tumour growth. This means that other 
cell types are responsible for shaping the immunological tumour-micromilieu. The role MCs 
play in innate and adaptive immunity has been grossly over-rated over past decades due to 
misleading results in Kit-mutant MC deficient mouse models. In particular, pharmacological 
MC activation by MC secretagogues was proposed as a novel adjuvant principle in 
vaccination. Also this concept was disproved by our group through experiments in novel, Kit-
independent MC deficiency models (Schubert et al. Mast cells do not mediate relevant 
adjuvant effects in adaptive immune responses to vaccination, submitted). Thus, 
development of new therapeutic approaches to modulate the immunological micromilieu 
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and shift inflammatory cell function from tumor-promotion to anti-tumor immunity should 
focus on cell types other than MCs. 
Numerous reports have suggested that MCs promote tumour neo-angiogenesis. These are 
mainly based on the positive correlation of MC density and blood vessel numbers in cancers 
and on expression of angiogenic factors by MCs, most prominently VEGF. In addition, 
Coussens et al. reported reduced angiogenesis in a single K14-HPV16 transgenic animal on 
a MC-deficient Kit-mutant background. We did not observe impaired tumour neo-
angiogenesis in the absence of MCs in our Kit-independent model. In parallel to the work 
described in this thesis, we also generated M5Cre+VEGF fl/fl mice with a selective 
inactivation of the VEGF gene in MCs and crossed this new strain to the K14-HPV16 model. 
This approach offers the opportunity to confirm the result obtained with our MC-deficient 
model by a complementary experiment based on a different principle. High resolution analysis 
of tumor blood vessel architecture by intra vital microscopy and in vivo vascular leakage 
studies are under way. This study is almost complete and does not reveal any role for MCs 
in angiogenesis in the K14-HPV16 tumor model (Ghouse et al., manuscript in preparation). 
While MCs have no role in spontaneous tumour growth in K14-HPV16 mice, it could still be 
possible that the presence or absence of MCs influences the response of the tumour to anti-
cancer chemo- or immunotherapy. In order to test this, MC-deficient and proficient mice would 
be treated with anti-cancer drugs, such as cisplatin or paclitaxel, and tested to determine 
whether MCs increase the efficacy of these therapeutic agents.  
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 Zusammenfassung  
Mastzellen sind langlebige Immunzellen, denen eine wichtige Rolle bei der Initiierung 
angeborener und adaptiver Immunantworten zugesprochen wird. Bei verschiedenen 
humanen Tumoren häufen sich viele Mastzellen im Tumorstroma und dessen Umgebung an, 
was nahelegt, dass Mastzellen eine wichtige Rolle in der Tumorbiologie spielen könnten. 
Experimentelle Studien, in genetischen Tumor-Mausmodellen, die auf mastzell-defiziente 
Mauslinien mit Kit-Mutationen gekreuzt wurden, lieferten Hinweise dafür, dass Mastzellen 
wichtige Tumor-begünstigende Funktionen ausüben. Diese Erkenntnisse sind jedoch kritisch 
zu betrachten, da  Kit-mutante Mäuse  neben ihrer Mastzell-Defizienz, weitere komplexe 
Veränderungen des Immunsystems aufweisen. Bestärkt werden diese Zweifel dadurch, dass 
zahlreiche publizierte Resultate, die mit Kit-mutanten Mäusen gewonnen wurden, in neuen, 
Kit-unabhängigen  Mausmodellen, nicht reproduziert werden konnten. Demzufolge bleibt der 
Einfluss von Mastzellen auf die Tumorbiologie weiterhin fraglich. Das Ziel dieser Studie war 
es, aufzuklären, ob Mastzellen an der Biologie von Hautkrebs beteiligt sind, der in einem 
Mausmodell durch das Humane Papilloma Virus (HPV) induziert wird. Dazu wird ein neues, 
Kit-unabhängiges Mausmodell verwendet. 
In K14-HPV16-transgenen Mäusen werden HPV-Onkogene konstitutiv in der Epidermis  
exprimiert, so dass eine epidermale Hyperplasie mit 100% Penetranz und bei 50% der Tiere 
ein spinozelluläres Karzinom (SCC)  auftritt. In diesem Modell war, basierend auf einer 
Kreuzung mit einem Kit-mutanten Mastzelldefizienz-Modell, beschrieben worden, dass 
Mastzellen Tumor-begünstigende Effekte vermitteln. Wir haben K14-HPV16-Mäuse mit der 
M5Cre R-DTA-Linie gekreuzt, in der Mastzellen sehr effizient und mit hoher Selektivität  
konstitutiv depletiert sind. Unerwarteter Weise hatte das Fehlen von Mastzellen weder 
Einfluss auf die Proliferation, noch auf die Apoptoserate von Keratinozyten  in allen Stadien 
der HPV-induzierten Neoplasie. Weiterhin führte das Fehlen von Mastzellen zu keinen 
nachweisbaren Veränderungen  in der  Zusammensetzung und Gen-Expression der 
inflammatorischen, hematopoietischen Zellinfiltrate des Tumor-Stromas. Dies zeigt, dass 
Mastzellen, im Gegensatz zu den bisherigen Annahmen, keine bedeutende Funktion in der 
‚Orchestrierung’ des Tumor-Mikromilieus  zugeschrieben werden kann. In Übereinstimmung 
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mit diesen Ergebnissen führte die Mastzell-Defizienz auch zu keinen nachweisbaren 
Veränderungen in Inzidenz, Wachstum oder Grading von SCCs in K14-HPV16-transgenen 
Mäusen. Zusammenfassend zeigen die  Ergebnisse dieser Studie, dass Mastzellen im K14-
HPV16 Mausmodell, trotz hoher Mastzelldichte im Tumorgewebe, keine Rolle bei der 
Krebsentstehung oder der neoplastischen Progression spielen. Unsere Ergebnisse machen 
zudem deutlich, wie wichtig die neuen, Kit-unabhängigen, Mausmodelle bei der Erforschung 
von in vivo Mastzellfunktionen sind. 
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 Summary 
Mast cells (MCs) are long-lived immune cells, which were reported to play an important role 
in initiating innate and adaptive immune responses against various infections. MCs 
accumulate in high numbers in the stroma and at the invasion front of various human cancers, 
suggesting a possible contribution by MCs to tumour growth. Experimental studies using 
crosses of MC-deficient Kit-mutant mouse strains with mouse models of epithelial cancers 
have provided evidence for important MC tumour-promoting functions. However, the complex 
alterations of the immune system that characterize Kit-mutant mice in addition to their MC 
deficiency, limit the interpretation of these findings. Numerous key observations made in Kit 
mutant mice were not reproduced in novel, Kit-independent mouse models of MC deficiency. 
Thus, the impact of MCs on tumour biology remains unclear. The aim of this study is to clarify 
the contribution of MCs to the biology of Human papilloma virus (HPV)-induced skin cancer 
in a Kit-independent mouse model of MC deficiency. 
In K14-HPV16 transgenic mice, HPV oncogenes are constitutively expressed in the epidermis 
resulting in epidermal hyperplasia with 100% penetrance and squamous cell carcinoma in 
about 50% of the animals. A cross to a Kit-mutant line suggested that MCs are important 
tumour promoters in this model. We crossed K14-HPV16 mice to M5Cre R-DTA line, in which 
MCs are constitutively depleted with high efficiency and selectivity. Unexpectedly, the loss of 
MCs neither affected keratinocyte proliferation indices nor altered keratinocyte apoptosis at 
any stage of HPV-induced neoplasia. Furthermore, the loss of MCs did not result in any 
detectable changes in composition and gene expression of the inflammatory hematopoietic 
cell infiltrate in the tumour stroma. This shows that, contrary to current belief, MCs have no 
important function in orchestrating the tumour micro milieu. In keeping with this finding, MC 
deficiency resulted in no detectable difference in the incidence growth or grading of SSC in 
K14-HPV16 transgenic mice. Collectively, these results show that, despite their high density 
in HPV-induced neoplasia, MC have no role in cancerogenesis or neoplastic progression in 
the K14-HPV16 mouse model. Our findings also emphasize the importance of novel Kit-
independent mouse models in the investigation of MC in vivo functions. 
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